

# JOURNAL OF **SWINE** HEALTH & PRODUCTION

Collection of oral fluids from group-housed sows fed with electronic feeders

*Pierdon MK, Martell AL, Parsons TD*

Antimicrobial resistance and virulence factors of *S suis* strains from Italian pigs

*Tedde MT, Pilo C, Frongia M, et al*

Bacteriophage supplementation to treat enterotoxigenic *E coli* in weaned pigs

*Han SJ, Oh Y, Lee CY, et al*

Reproductive performance in females on increased feed during late gestation

*Gonçalves MAD, Dritz SS, Tokach MD, et al*



# Journal of Swine Health and Production

(ISSN 1537-209X) Volume 24, Number 5; September and October 2016  
Copyright © 2016 American Association of Swine Veterinarians



The *Journal of Swine Health and Production* is published by the American Association of Swine Veterinarians.

Opinions expressed in this publication are those of the individual authors and do not necessarily reflect the endorsement, official attitude, or position of the American Association of Swine Veterinarians, the *Journal of Swine Health and Production*, or any Industry Support Council member.

The *Journal of Swine Health and Production* is a refereed publication and is a benefit of membership in the American Association of Swine Veterinarians. Subscriptions (\$US) are available to nonmembers at \$145.00 per year (six issues) for United States, Canada, and Mexico. The cost is \$180.00 for all countries outside North America. For inquiries regarding membership or subscriptions, please contact

AASV  
830 26<sup>th</sup> Street, Perry, IA 50220-2328  
Tel: 515-465-5255; Fax: 515-465-3832  
E-mail: [aasv@aasv.org](mailto:aasv@aasv.org)

Editorial questions, comments, and inquiries should be addressed to Karen Richardson, Publications Manager:  
Tel: 519-856-2089; Fax: 519-763-3117;  
E-mail: [pub\\_mgr@aasv.org](mailto:pub_mgr@aasv.org)

## DISCLAIMER

Scientific manuscripts published in the *Journal of Swine Health and Production* are peer reviewed. However, information on medications, feed, and management techniques may be specific to the research or commercial situation presented in the manuscript. It is the responsibility of the reader to use information responsibly and in accordance with the rules and regulations governing research or the practice of veterinary medicine in their country or region.

## AASV officers

**GEORGE CHARBONNEAU**  
President,  
[gcharbonneau@southwestvets.ca](mailto:gcharbonneau@southwestvets.ca)

**ALEX RAMIREZ**  
President-elect,  
[ramireza@iastate.edu](mailto:ramireza@iastate.edu)

## AASV Staff

**TOM BURKGREN**  
Executive Director,  
[burkgren@aasv.org](mailto:burkgren@aasv.org)

**SUE SCHULTEIS**  
Associate Director,  
[aasv@aasv.org](mailto:aasv@aasv.org)

## JSHAP Staff

**TERRI O'SULLIVAN**  
Executive Editor, [pub\\_mgr@aasv.org](mailto:pub_mgr@aasv.org)

**JUDI BELL**  
Associate Editor, [pub\\_mgr@aasv.org](mailto:pub_mgr@aasv.org)

**KAREN RICHARDSON**  
Publications Manager, [pub\\_mgr@aasv.org](mailto:pub_mgr@aasv.org)

**TINA SMITH**  
Graphic Designer, Advertising Coordinator,  
[tina@aasv.org](mailto:tina@aasv.org)

## Editorial Board

**GLEN ALMOND**  
North Carolina, [glen\\_almond@ncsu.edu](mailto:glen_almond@ncsu.edu)

**JANE CHRISTOPHER-HENNINGS**  
South Dakota, [Jane.Hennings@sdstate.edu](mailto:Jane.Hennings@sdstate.edu)

**JOHN HARDING**  
Saskatchewan, [john.harding@usask.ca](mailto:john.harding@usask.ca)

**JAMES KOBER**  
Michigan, [svsmi@sbcglobal.net](mailto:svsmi@sbcglobal.net)

**DARIN MADSON**  
Iowa, [madson@iastate.edu](mailto:madson@iastate.edu)

**ADAM MOESER**  
Michigan, [moeserad@cvm.msu.edu](mailto:moeserad@cvm.msu.edu)

**SCANLON DANIELS**  
Vice President,  
[scanlon@circleh.info](mailto:scanlon@circleh.info)

**RON BRODERSON**  
Immediate Past President,  
[ronb@wholehogai.com](mailto:ronb@wholehogai.com)

**HARRY SNELSON**  
Director of Communications,  
[snelson@aasv.org](mailto:snelson@aasv.org)

**DAVE BROWN**  
Webmaster/IT Specialist,  
[dave@aasv.org](mailto:dave@aasv.org)

**LAURA BATISTA AND SANDRA PÉREZ**  
Spanish translators

**SERGE MESSIER**  
French translator

**ZVONIMIR POLJAK**  
Consulting Epidemiologist

**THOMAS PARSONS**  
Pennsylvania, [thd@vet.upenn.edu](mailto:thd@vet.upenn.edu)

**ALEX RAMIREZ**  
Iowa, [ramireza@iastate.edu](mailto:ramireza@iastate.edu)


**MIKE TOKACH**  
Kansas, [mtokach@ksu.edu](mailto:mtokach@ksu.edu)

**BETH YOUNG**  
Sweden, [byoung.dvm@gmail.com](mailto:byoung.dvm@gmail.com)

**JEFF ZIMMERMAN**  
Iowa, [jjzimm@iastate.edu](mailto:jjzimm@iastate.edu)

*Journal of Swine Health and Production* is indexed in ISI® *Focus On: Veterinary Science & Medicine*®, and in *CAB Abstracts*, Euroscience VETLINE on CD-ROM





Download this issue to your iPad or Android tablet at <https://www.aasv.org/shap/issues/v24n5/v24n5jshap.pdf>



### About the cover...

Cross-bred pigs in a Japanese farrow-to-finish farm

*Photo courtesy of  
Dr Brian Payne*

### AASV Resources online at

<https://www.aasv.org>

#### Author guidelines

<https://www.aasv.org/shap/guidelines.pdf>

#### Journal of Swine Health and Production

<https://www.aasv.org/shap.html>

#### Membership information

<https://www.aasv.org/aasv/membership.html>

#### Subscription information

<http://ecom.aasv.org/journal>

#### Upcoming meetings


<https://www.aasv.org/meetings>

## TABLE OF CONTENTS

|  |     |
|--|-----|
| President's message .....  | 241 |
| Executive Editor's message .....   | 243 |
| Why do you do what you do?.....  | 245 |
| Use of ropes to collect oral fluids from gestating sows housed in dynamic groups and fed via electronic sow feeder.....  | 246 |
| <i>Pierdon MK, Martell AL, Parsons TD</i>  |     |
| Antimicrobial resistance and virulence factors of <i>Streptococcus suis</i> strains isolated from diseased pigs in southern Italy (Sardinia) .....                             | 253 |
| <i>Tedde MT, Pilo C, Frongia M, et al</i>  |     |
| Efficacy of dietary supplementation of bacteriophages in treatment of concurrent infections with enterotoxigenic <i>Escherichia coli</i> K88 and K99 in postweaning pigs ..... | 259 |
| <i>Han SJ, Oh Y, Lee CY, et al</i>   |     |
| Fact sheet – Impact of increased feed intake during late gestation on reproductive performance of gilts and sows.....  | 264 |
| <i>Gonçalves MAD, Dritz SS, Tokach MD, et al</i>   |     |
| News from the National Pork Board .....  | 267 |
| AASV news .....  | 271 |
| Advocacy in action .....   | 277 |
| Upcoming meetings .....  | 279 |

“...it occurred to me that my clients routinely go through catastrophic events such as porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, production failures, fires, and other major misfortunes that are every bit as devastating as a tornado.”

*Quoted from Dr Brian Schantz's message, page 245*



**For all the  
twists and turns.**

**The first isotonic protein drink.**

What if there were a new solution to help pigs thrive as they transition through key milestones? From Day 2, Tonisity Px helps pigs cope with stress, decreases pre-weaning mortality, increases weaning weights and improves gut health. With a taste profile pigs crave, Px provides the hydration and intestinal support needed to get them off to a fast, healthy start.

**Learn how you can help your producers improve their return on investment for every litter at [tonisity.com](https://tonisity.com).**

**Tonisity Px**

## “Don't fear criticism”

When I pass by the Valley Veterinary Clinic I still experience a flood of memories. I worked there as a summer student. I remember sleeping over a horse stable and eating a lot of peanut butter and jam sandwiches in an attempt to save money for school. I remember being asked to take the lead on some clinical investigations. I remember learning that the way you present the values of your practice to the public is important. Mostly I remember the time spent with a great group of veterinarians and staff.

Dr John Stinson, one of founding partners, was a very hard worker. He also knew how to find the humor in almost any situation. He seemed, to me, to be fearless and did not shy away from a challenge. John was one of those veterinarians that had been steeped in veterinary medicine for his entire life. John's father, Dr W. J. Stinson, was a local legend in the farming community and a self-proclaimed “horse doctor.” John had witnessed the evolution of companion animal practice as he grew up and then when he started his own practice. The values placed on pets in his practice were very different from those in his father's practice.



John's practice was a place where locals could bring a stray animal that had been injured. Whether it was a “dog hit by car” or “deer hit by car,” John was all about trying to do what was right for the animal. There were, however, practical limits to what a small clinic could do. On one occasion a stray dog with no tags was brought to the clinic. The dog was treated and housed while they tried to find the owner or a new home. With little prospect of finding the owner or a new home John eventually elected to euthanize the dog.

---

*“I remember learning that the way you present the values of your practice to the public is important.”*

---

They say that “no good deed goes unpunished!” A short while later, the dog's owner showed up at the clinic looking for the missing dog. The owner was told that the dog had been taken in and treated, but when no one claimed ownership or adopted the dog, it was eventually euthanized. Despite what John had done to try to help, the owner thought he should have done even more. Soon thereafter an official complaint was registered and there were some tough days ahead for John. We could tell when John got another criticism, as he would walk around the clinic with a long towel wrapped around his neck, upstretched towards the ceiling, and he would ask if anyone had a small table or chair that he could borrow for a short while.

John always seemed to have an endless supply of quotations that he could draw on for any particular situation. In this situation, where he was trying to do the right thing for these strays, he seemed to take some comfort that summer from one particular anonymous quote that went as follows. “Don't fear criticism. The galleries are full of critics. They play no ball, they fight no fights. They make no mistakes because they attempt nothing. Down in the arena are the doers. They make mistakes.”<sup>1</sup> I wrote it down, committed it to memory, and have never forgotten it since.

It was not until recently that I learned that this quote actually came from General David

Monroe Shoup.<sup>2</sup> Shoup was an Indiana farm kid who had joined the Reserve Officer Training Corp in order to pay for his college education. Shoup stayed in the military after graduation. As a colonel in the Marine Corps he was awarded the Medal of Honor for his actions in liberating the Tarawa Atoll in WW II. He eventually became the 22<sup>nd</sup> Commandant of the US Marine Corps and part of the Joint Chiefs of Staff during the Eisenhower administration. After retiring from the Marine Corps, Shoup became a very outspoken anti-Vietnam activist. For speaking his mind and standing by his convictions on that particular issue he received a great deal of public criticism.

It would have been easier for Dr Stinson to avoid criticism had he not tried to offer help for those animals in need. From his frame of reference he thought that he had made an ethical decision to euthanize that particular dog. He was being pragmatic and understood that resources were not limitless. Today we are experiencing a similar change in societal values and the “social license” needed for producing food animals.

The troubles eventually passed for John, but not without some adjustment to public expectations. The good news was that John continued to help animals in need when he could. In fact, one timid cat that he had rescued that summer headed back to school with me, and she was a part of my young family for 14 years. Often in life we can find ourselves in the right place at the right time, with an opportunity to effect change for the good. We may make a mistake as we try. We may be the target of criticism. Perhaps we should learn to wear that criticism as if it were a badge of honor for trying to do the right thing for the animals in our care.

### References

1. [www.quotes.net/quote/17506](http://www.quotes.net/quote/17506).
2. David M. Shoup. [https://en.wikipedia.org/wiki/David\\_M.\\_Shoup#Commandant\\_of\\_the\\_Marine\\_Corps](https://en.wikipedia.org/wiki/David_M._Shoup#Commandant_of_the_Marine_Corps).

George Charbonneau, DVM  
AASV President







**KAVAUULT® PIGS GET  
OFF TO A STRONG START.**

## Introducing Kavault (avilamycin)

Reduce the incidence and overall severity of diarrhea in the presence of pathogenic *E. coli* in groups of weaned pigs. Kavault is an easy, cost-effective way to deliver more thriving pigs out of the nursery.

Elanco

**Kavault**

- Animal-use only
- Zero-day withdrawal
- New antibiotic class
- Excellent safety profile in the US (worldwide registrations, established MRL)
- Early intervention during critical nursery phase

Learn more at [elanco.us](http://elanco.us).

### Kavault directions for use

For reduction in incidence and overall severity of diarrhea in the presence of pathogenic *Escherichia coli* in groups of weaned pigs.

Feed at 73 grams avilamycin per ton of Type C medicated feed (80 ppm) as the sole ration for 21 consecutive days. The veterinarian may direct feeding for up to a total of 42 consecutive days, based on clinical assessment. Feed to pigs that are at risk of developing, but not yet showing clinical signs of, diarrhea in the presence of pathogenic *Escherichia coli*.

- CAUTION: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.

Elanco, Full Value Pigs™ Kavault and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.  
© 2016 Eli Lilly and Company, its subsidiaries or affiliates. USSBUKAV00011

  
**FULL VALUE PIGS™**

**Elanco**

1-800-428-4441  
[www.elanco.us](http://www.elanco.us)



## Animal-use statements

If you have submitted your own manuscript or have been involved as a co-author, you are probably very aware that the *Journal of Swine Health and Production* (JSHAP) has many different policies and procedures. These policies, such as the requirement for a conflict-of-interest statement,<sup>1</sup> are in place to help maintain the rigour of the scientific peer-review process and uphold the ethical policies of the journal. Another important *Journal of Swine Health and Production* requirement, which is outlined in the author guidelines, is that authors must provide a statement regarding any animal use that is in a presented manuscript. Specifically, this statement is to be placed at the beginning of the “materials and methods” section of the manuscript. So what is an animal-use statement exactly? Simply, it is a statement made by the authors that any animal use that occurred in the research conducted was done in a humane, necessary, and responsible manner and that the procedures used were approved by a third party or organization with authority and (or) knowledge in the species used for research purposes, ie, pigs.

Here at the University of Guelph, where I conduct the majority of my research, all animals used for research (or teaching) purposes

are overseen by the university's Animal Care Committee (ACC). The ACC is made up of a variety of individuals and includes members of the public, faculty who use animals in research, faculty who do not use animals in research, veterinarians, and graduate students, to name a few. This committee reviews all applications from researchers who wish to use animals in research and ensures that a research project has undergone a scientific merit review. The University of Guelph's animal-use program follows and abides by guidelines set by the Canadian Council of Animal Care in science (CCAC) for using animals in research.<sup>2</sup> The CCAC provides nationally and internationally recognized standards for the use of animals in research.<sup>2</sup> Additionally, the CCAC oversees all animal use and animal-use programs in Canadian institutions. Researchers at universities across North America are quite used to these types of committees and animal-use policies, including the requirement to have all animal use reviewed and approved by their institution's animal care and use department or committee. So most manuscripts submitted to JSHAP that originate from an academic institution have an appropriate animal-use protocol in place and an appropriate animal-use statement provided.

It can, however, be challenging to obtain an appropriate animal-use statement with case reports and clinical trials that are conducted by individuals outside the academic environment. This is because there occasionally may be lack of a peer review or third-party review of the study protocol prior to any animal use. This step is important, as it equates to a peer review of a scientific manuscript. However, a case report isn't meant to be an original research project, so obviously no pre-review would have been conducted. It is extremely important to me that the journal receive case reports and original research manuscripts related to research projects that are conducted on farms by individuals outside academic institutions, ie, practicing veterinarians. For case reports, a statement

---

*“Another important Journal of Swine Health and Production requirement, which is outlined in the author guidelines, is that the authors must provide a statement regarding any animal use that is in a presented manuscript.”*

---

that the farm from which the case report originated follows an appropriate animal-care program and that the case was overseen by a properly trained individual, such as the herd veterinarian, is considered appropriate. In Canada, for example, the Animal Care Assessment (ACA) program is utilized and often cited. For other research projects conducted it is important as a researcher to obtain a review of any animal use, ideally by a third party. It is important to note that animal-use regulations do vary slightly by region, ie, North America versus Europe, and so there is variability in the wording of these statements. However, JSHAP requires an animal-use statement for all manuscripts that have used animals.

If you need help with your animal-use statement, please do not hesitate to contact the journal office.

### References

1. O'Sullivan T. Conflict of interest [editorial]. *J Swine Health Prod.* 2013;21:7.
2. Canadian Council on Animal Care in Science. Available at <http://www.ccac.ca/en/>. Accessed 1 July 2016.

Terri O'Sullivan, DVM, PhD  
Executive Editor



# ENROFLOX® 100 your partner IN PROFIT

Approved for the treatment and control of Swine Respiratory Disease (SRD) associated with *Actinobacillus pleuropneumoniae* (APP), *Pasteurella multocida*, *Haemophilus parasuis* and *Streptococcus suis*

## FOR VETERINARY USE ONLY

For use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. Swine intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose. Use with caution in animals with known or suspected CNS disorders. Observe label directions and withdrawal times. See product labeling for full product information.



- FDA-approved, one-dose Swine Respiratory Disease (SRD) treatment
- Same active ingredient found in Baytril® 100
- Approved for pigs of all ages

[www.norbrookinc.com](http://www.norbrookinc.com)

0316-495-101A

Baytril is a registered trademark of Bayer Animal Health  
The Norbrook logos and Enroflox® are registered trademarks of Norbrook Laboratories Limited.



ANADA 200-495, Approved by FDA

## Enroflox® 100 (enrofloxacin)

100 mg/mL Antimicrobial  
Injectable Solution

**For Subcutaneous Use in Beef Cattle, Non-Lactating Dairy Cattle and Swine Only.**

**Not for Use in Female Dairy Cattle 20 Months of Age or Older Or In Calves To Be Processed For Veal.**

**Brief Summary:** Before using Enroflox® 100, consult the product insert, a summary of which follows.

**CAUTION:** Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (U.S.A.) law prohibits the extra-label use of this drug in food-producing animals.

**PRODUCT DESCRIPTION:** Each mL of Enroflox 100 contains 100 mg of enrofloxacin. Excipients are L-arginine base 200 mg, n-butyl alcohol 30 mg, benzyl alcohol (as a preservative) 20 mg and water for injection q.s.

### INDICATIONS:

**Cattle - Single-Dose Therapy:** Enroflox 100 is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, *H. somni* and *M. bovis*.

**Cattle - Multiple-Day Therapy:** Enroflox 100 is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida* and *Histophilus somni* in beef and non-lactating dairy cattle.

**Swine:** Enroflox 100 is indicated for the treatment and control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Haemophilus parasuis* and *Streptococcus suis*.

### RESIDUE WARNINGS:

**Cattle:** Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

**Swine:** Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.

**HUMAN WARNINGS:** For use in animals only. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive

exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. For customer service, to obtain a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions, call Norbrook at 1-866-591-5777.

### PRECAUTIONS:

The effects of enrofloxacin on cattle or swine reproductive performance, pregnancy and lactation have not been adequately determined. The long-term effects on articular joint cartilage have not been determined in pigs above market weight.

Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

Enroflox 100 contains different excipients than other enrofloxacin products. The safety and efficacy of this formulation in species other than cattle and swine have not been determined. Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. See Animal Safety section for additional information.

**ADVERSE REACTIONS:** No adverse reactions were observed during clinical trials.

### ANIMAL SAFETY:

In cattle safety studies, clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of depression, inappetence and incoordination were observed when a dose of 50 mg/kg was administered for 3 days. An injection site study conducted in feeder calves demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue and underlying muscle. In swine safety studies, incidental lameness of short duration was observed in all groups, including the saline-treated controls. Musculoskeletal stiffness was observed following the 15 and 25 mg/kg treatments with clinical signs appearing during the second week of treatment. Clinical signs of lameness improved after treatment ceased and most animals were clinically normal at necropsy. An injection site study conducted in pigs demonstrated that the formulation may induce a transient reaction in the subcutaneous tissue.

Norbrook Laboratories Limited,

Newry, BT35 6PU, Co. Down, Northern Ireland

101 March 2015

The Norbrook logos and Enroflox® are registered trademarks of Norbrook Laboratories Limited.





## Why I do what I do

### The winds of change

I have been practicing veterinary medicine in northeast Nebraska for nearly 30 years. I started in a traditional mixed practice seeing dairy, beef, swine, sheep, goats, horses, dogs, and cats daily. Many of my clients were small diversified producers. I not only treated their sick animals, but together we celebrated, mourned, worried, debated, worshipped, worked, and played. Our relationships were personal and strong. In the early to mid-1990s, the farming community began to change rapidly. The small family farm evaporated, being replaced with larger, more specialized systems. Adapting, in 1997 I started a 100% swine practice focusing on sow-unit management and veterinary consultation. Over the years I evolved into a diagnostician, a human resource advisor, a standard-operating-procedure author, and an efficiency policeman. Practice, along with my approach, had changed dramatically. I found myself getting more and more impersonal, clinical, and detached – not the approach I had used as a young veterinarian. I slipped into this approach as more of my work was with employees and absentee owners. It took a little wind to wake me up.



June 16, 2014, was a hot humid day and I spent most of the day looking at pigs near Pilger, Nebraska, 40 miles south of where I live. An hour after I left, twin F4 tornadoes ripped through Pilger and the surrounding community. The tornados caused two deaths and over \$20,000,000 in damages. The town was basically leveled. I knew several people who lost their homes, farms, and livestock.

June 17, 2014, was another hot humid day. I thought about heading south to Pilger to help clean up, but I was pretty busy. Besides, I had called a couple people to see if they needed help, but had no response to my messages. Later, I again thought about heading south and helping, but there were thistles in the pasture that needed spraying.

---

*"I no longer want to be the one who calls and offers help. I want to be the one who shows up unannounced."*

---

By 7:30 PM it was getting hazy and cloudy when suddenly lightning flashed to the west. I parked the sprayer and went into the house for an iced tea. From my west porch I was shocked to see a small thin tornado snaking from the sky down to the horizon. It appeared to be only a few miles northwest of our place. I quickly grabbed my wife and jumped in the car (exactly what you are NOT supposed to do). For the next 2½ hours we watched as the tornado moved excruciatingly slowly in and out of the clouds. My business partner lives about a mile from us and our clinic is located on his place. I was calling him frequently to check on things. At 10:00 PM he reported that everything had moved away from his place. At 10:15 PM he called.... everything was gone except his house. The tornado had turned, heading straight through his place and several others in the neighborhood.

His house was damaged, but livable. Our clinic and everything else – records, medicine, computers, and office equipment – was gone. At daylight, people started showing up: friends, family,

acquaintances, drug reps, clients, employees, neighbors, and strangers. For the next several days, literally hundreds of people helped us clean up, fed us, encouraged us, and helped move us to a temporary building. I am ashamed to admit, just the day before, I had rationalized why I didn't need to help others in the exact same predicament. It was a very humbling and poignant moment for me. I was reminded of several things while going through this ordeal. The more obvious things were 1) review adequacy of insurance annually, and 2) back up your computers daily to an off-site spot (ie, cloud). The less obvious but much more important reminder was to review my approach to producers and employees during the tough times.

The loss of property is only a part of going through a challenging event like this. Overwhelming feelings of depression, frustration, and exhaustion also play a role. For me, the outpouring of unsolicited support helped to minimize those feelings.

On reflection, it occurred to me that my clients routinely go through catastrophic events such as porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, production failures, fires, and other major misfortunes that are every bit as devastating as a tornado. As their veterinarian, I am frequently in a unique position to help deal with these situations. I may have done an adequate job responding to the practical details of these events, but I have been abysmal in helping with the depression, discouragement, and frustration that follow these crises. I have not gone that extra unsolicited mile to make that greater difference. Strangely, I am thankful that a little wind woke me up. I no longer want to be the one who calls and offers help. I want to be the one who shows up unannounced. Why do I do what I do? To make a real difference.

Brian Schantz, DVM



# Use of ropes to collect oral fluids from gestating sows housed in dynamic groups and fed via electronic sow feeder

Meghann K. Pierdon, VMD; Amy L. Martell, VMD; Thomas D. Parsons, VMD, PhD, DACAW

## Summary

**Objectives:** The primary objective of this study was to understand how group-housed sows interact with ropes as a tool for collecting oral fluids. The secondary objective was to provide evidence that oral fluids collected from gestating sows housed in pre-implantation dynamic groups can be a useful sample for porcine reproductive and respiratory syndrome (PRRS) surveillance.

**Materials and methods:** Oral-fluid samples were collected 1 day per week for 3 weeks at a 750-sow PRRS-negative facility with two pens housing pre-implantation dynamic groups for gestating sows fed via an electronic

sow feeder (ESF) system. Ropes were placed and activity filmed with handheld cameras. Videos were analyzed for number of sows to chew, time to first chew (TFC), and number of aggressive events. Serum samples were collected from a subset of sows that had contributed oral fluids on this farm, as well as from sows on a second similar farm that was PRRS-positive.

**Results:** The average number of sows contacting a rope during sampling was  $19.9 \pm 1.2$  ( $n = 13$  videos). Repeated sampling significantly influenced TFC (Kruskal-Wallis;  $P < .05$ ). Oral-fluid PRRS enzyme-linked

immunosorbent assay sample-to-positive (S:P) ratios for individual ropes correlated with the mean serum S:P ratio of a subset of 10 sows that contacted the rope.

**Implication:** Rope sampling will likely provide a method for readily collecting oral-fluid samples from sows housed in dynamic groups and fed with an ESF.

**Keywords:** swine, group housing, oral fluids, pen gestation, porcine reproductive and respiratory syndrome virus testing

**Received:** August 28, 2015

**Accepted:** March 22, 2016

## Resumen - Uso de cuerdas para coleccionar fluidos orales de hembras gestantes alojadas en grupos dinámicos y alimentadas vía alimentador de hembras electrónico

**Objetivos:** El objetivo principal de este estudio fue entender como interactúan las hembras alojadas en grupos con cuerdas como material para recolectar fluidos orales. El objetivo secundario fue proveer evidencia de que los fluidos orales colectados de hembras gestantes alojadas en grupos dinámicos pre implantación puede ser una muestra útil para el monitoreo del síndrome respiratorio y reproductivo porcino (PRRS por sus siglas en inglés).

**Materiales y métodos:** Se colectaron muestras de fluidos orales 1 día a la semana por 3 semanas en un edificio de 750 hembras negativo al PRRS con dos corrales alojando grupos dinámicos pre implantación para hembras gestantes alimentadas vía un

sistema alimentador de hembras electrónico (ESF por sus siglas en inglés). Se colocaron cuerdas y se filmó la actividad con cámaras manuales. Se analizaron los videos para ver cuántas hembras masticaron, tiempo para la primera masticación (TFC por sus siglas en inglés), y número de eventos agresivos. Se colectaron muestras de suero de un subconjunto de hembras que habían contribuido fluidos orales en esta granja, así como de hembras en una segunda granja similar que resultó positiva al PRRS.

**Resultados:** El número promedio de hembras que hicieron contacto una cuerda durante el muestreo fue  $19.9 \pm 1.2$  ( $n = 13$  videos). El muestreo repetido influenció significativamente el TFC (Kruskal-Wallis;  $P < .05$ ). Los índices muestra a positivo (S:P por sus siglas en inglés) del ensayo por inmunoabsorción ligado a enzimas del PRRS del fluido oral para las cuerdas individuales se correlacionaron con el ratio S:P del suero promedio de

un subconjunto de 10 hembras que hicieron contacto con la cuerda.

**Implicación:** El muestreo de cuerda probablemente proveerá un método para coleccionar fácilmente muestras de fluido oral de hembras alojadas en grupos dinámicos y alimentados con un ESF.

## Résumé - Utilisation de cordes pour récolter du fluide oral de truies gestantes logées dans des groupes dynamiques et nourries via un distributeur électronique d'aliments

**Objectifs:** L'objectif primaire de la présente étude était de comprendre comment les truies logées en groupe interagissent avec des cordes comme outil de prélèvement de fluide oral. Le second objectif était de fournir des évidences que les fluides oraux prélevés chez des truies gestantes logées dans des groupes dynamiques pré-implantation peuvent être des échantillons utiles pour la surveillance du syndrome reproducteur et respiratoire porcine (SRRP).

**Matériels et méthodes:** Des échantillons de fluides oraux ont été prélevés 1 jour par semaine pendant 3 semaines, sur un site hébergeant 750 truies négatives pour le SRRP, dans deux parcs logeant des groupes dynamiques pré-implantation de truies gestantes nourries

University of Pennsylvania Department of Clinical Studies, School of Veterinary Medicine.

**Corresponding author:** Dr Meghann K. Pierdon, 382 West Street Road, Kennett Square, PA 19348; Fax: 610-925-8134; Tel: 610-925-6203; E-mail: [mpierdon@vet.upenn.edu](mailto:mpierdon@vet.upenn.edu).

This article is available online at <http://www.aasv.org/shap.html>.

Pierdon MK, Martell AL, Parsons TD. Use of ropes to collect oral fluids from gestating sows housed in dynamic groups and fed via electronic sow feeder. *J Swine Health Prod.* 2016;24(5):246-252.



via un distributeur électronique d'aliment pour truie (DEAT). Des cordes ont été placées et les activités filmées avec des caméras tenues à la main. Les vidéos ont été analysées pour déterminer le nombre de truies qui ont mâché, le délai avant la première mâchée (DPM), et le nombre d'événements agressifs. Des échantillons de sérum ont été prélevés sur cette ferme d'un sous-groupe de truies qui avaient contribué des fluides oraux, de même que de truies sur une autre ferme similaire dont les animaux étaient positifs pour SRRP.

**Résultats:** Le nombre moyen de truies en contact avec une corde durant l'échantillonnage était  $19,9 \pm 1,2$  ( $n = 13$  vidéos). Des échantillonnages répétés ont influencé de manière significative le DPM (Kruskal-Wallis;  $P < .05$ ). Les rapports échantillon-résultats positifs (E:P) pour l'épreuve immuno-enzymatique de détection du SRRP à partir des fluides oraux pour des cordes individuelles étaient corrélés avec le rapport sérique moyen E:P d'un sous-groupe de 10 truies qui ont été en contact avec la corde.

**Implication:** L'échantillonnage au moyen d'une corde sera fort probablement une méthode pour prélever facilement des échantillons de fluides oraux à partir de truies logées en groupes dynamiques et nourris avec un DEAT.

Oral fluids as a diagnostic sample to detect pathogens in swine was first described in the 1970s.<sup>1</sup> The use of rope to obtain samples of oral fluids from growing swine is a more recent advance.<sup>2,3</sup> This approach has been applied as a diagnostic tool for successful detection of pathogens in pigs at many additional stages of production: suckling piglets,<sup>4</sup> replacement gilts,<sup>5</sup> and individually housed boars<sup>6</sup> and sows.<sup>7</sup> Collection of oral fluids from sows in gestation stalls with individual ropes may not be practical when seeking a minimum sample size of 30 or more. However, group-housed sows do not face this same constraint, as multiple animals can access a single rope, and thus rope sampling promises to be much more efficient in pens of sows. To our knowledge, no research has been published on the use of ropes for collection of oral fluids for disease monitoring in group-housed sows.

Environmental enrichment studies have shown that sows housed in groups chew on cotton ropes.<sup>8</sup> However, several factors need to be addressed when examining how to optimize the use of ropes for collection of

oral fluids from gestating sows. First, while over 80% of the growing pigs in a pen interact with the rope in 60 minutes,<sup>9</sup> similar information is not available for sows. Thus, it is important to understand how many sows in a given pen chew on the rope. Second, unlike growing pigs, sows are maintained in a herd for years instead of months and could be sampled repeatedly during their lives. The number of individually housed boars and sows that can be successfully sampled increases with repeated exposure to a rope.<sup>6,7</sup> Thus, it is also critical to understand if repeated sampling impacts the number of animals interacting with the rope in group-housed sows. Third, it is also important to determine if oral fluids from the same or a different population of animals is captured when ropes are repeatedly introduced to the same group of animals. And finally, the specific animal interacting with the rope is likely also important. Social hierarchy develops when gestating sows are housed in groups, impacting aggression<sup>10</sup> and the order in which they eat,<sup>11,12</sup> and may impact their interaction with novel objects such as ropes. Furthermore, the social rank of individuals within the group has been shown to influence the animals' immune stimulation and subsequently may influence disease status.<sup>13</sup> Several different types of housing systems are employed for gestating sows that impact the number of animals in a pen, the size of the pen, the shape of the pen, and likely the way sows interact with the ropes hung in the pen. This study explored the applicability of oral-fluid testing in group-housed sows (> 100 sows per pen) with sows mixed 1 to 3 days after the last insemination and prior to implantation of the embryos (pre-implantation groups). These groups were also dynamic, since sows were removed to go to farrowing every other week, and sows were added to the pen every other week.<sup>14,15</sup> This study was designed to examine how many animals the rope sample represents, how experience impacts the time it takes sows to interact with the rope, and how social status affects oral-fluid sampling in terms of the animals that interact with the rope, in a single type of group sow housing.

## Materials and methods

Each farm had current Pork Quality Assurance certification, which provides guidelines that directed animal care.

## Study overview

The primary objective of this study was to understand how group-housed sows interact

with ropes as a tool for collecting oral fluids. The aim was to quantify the number of sows that interacted with ropes during a short sampling period (approximately 60 minutes) and to explore a limited number of factors that, on the basis of our experience in pen gestation, had the potential to impact sow-rope interactions. For a variety of logistical and biosecurity reasons, this part of the study was carried out on a farm negative for porcine reproductive and respiratory syndrome (PRRS). This farm is referred to as Study Farm 1.

A secondary objective of this study was to provide some evidence that oral fluids collected from gestating sows housed in pre-implantation dynamic groups can be a useful sample for PRRS surveillance. A second farm, which was PRRS-positive, was recruited to participate in the study, and this farm is referred to as Study Farm 2. The second farm was chosen on the basis of its similarities to the initial study farm. The details of the two study farms are described subsequently. Data was collected in August of 2013 on Study Farm 1 and September of 2013 on Study Farm 2.

## Description of study farms

**Study Farm 1.** The main part of the study, conducted on Study Farm 1, was used for the collection of all behavioral data presented. The farm was an owner-operated, 700-sow, farrow-to-wean, PRRS-negative facility that had managed gestating sows housed in pre-implantation dynamic groups and fed with electronic sow feeding since 2007. Sows (PIC 1050; PIC, Hendersonville, Tennessee) were housed in two pens, and gilts were housed in a separate pen. Our study was conducted only in pens containing sows.

**Study Farm 2.** This farm was recruited to supplement findings on the utility of oral-fluid samples from group-housed sows for PRRS surveillance. The farm was an owner-operated, 1400-sow, farrow-to-wean, PRRS-positive facility. At the time of the study, the facility was weaning PRRS-positive pigs, determined by polymerase chain reaction testing, and was vaccinating quarterly with a modified-live PRRS vaccine (Ingelvac PRRS MLV; Boehringer Ingelheim Vetmedica Inc, St Joseph, Missouri). This facility had managed gestating sows, housed in dynamic pre-implantation groups and fed with electronic sow feeding, since 2008. Choice Genetics CG32 sows (Choice Genetics, West Des Moines, Iowa) were housed in four pens, with gilts housed in a separate pen. The study was conducted only in pens containing sows.



**Common practices and designs of the two study farms.** Each sow pen housed approximately 175 animals and was equipped with three electronic sow-feeding stations (Compident VI; Schauer Agrotechnics, Prambachkirchen, Austria). The feed system turned on daily at midnight and closed when all animals had eaten, which typically was between 2 and 4 PM. Sows were fed a standard corn-soy diet according to their body condition. About 30 newly bred sows, or approximately 17% of the pen inventory, were introduced to a pen every 14 days, after the movement of a corresponding number of late-term sows to farrowing. Pens were designed to house sows with a space allocation of 1.9 to 2.1 m<sup>2</sup> per sow. Flooring was slatted, with the exception of solid areas provided for lying and sleeping (Figure 1).

### Behavioral observations

Behavioral data was collected only on Farm 1.

### Sow-rope interactions

**Data collection.** Sow interactions with both the rope and her cohort at the rope site were video recorded via handheld cameras (Handycam; Sony, New York, New York). The observers holding the cameras also called out the sows' ear tag numbers as the sows contacted the rope to individually identify sows. This information was recorded on the


audio track of the video recording and was available for subsequent analysis. Video recording started immediately after placing the ropes in the pen at approximately 8 AM. Videos were of varying lengths due to the challenges associated with collecting behavioral data in an on-farm setting, but data analysis was capped at the first 55 minutes of each video to standardize the length.

**Data analysis.** Videos were analyzed off-line using the Noldus Observer XT V. 10.5 software (Noldus Information Technology Inc, Leesburg, Virginia) to identify sow-rope and sow-sow interactions. A chew event was defined as the rope being in the mouth of a sow. An aggressive event was defined as a sow biting or head butting another sow at the rope. The following metrics were tallied for each video from the individual sow events: number of sows to chew on a rope (NSC), time to first chew on a rope (TFC), and number of aggressive events at the rope (NAE). The cameras recorded at 60 frames per second and thus provide an effective temporal resolution in our measurements of one data point every 16.7 milliseconds (ms). The software is configured to report the temporal resolution of data collection as 0.02 seconds after converting 16.7 ms to seconds and then rounding to two significant figures. A replicate (n) was defined as the observations from

a site where ropes were hung that were videotaped with a single camera. Rope-hanging sites were randomly assigned, using a random number generator, to have either one or two ropes.

**Feed rank.** Feed order was saved daily by the ESF computer and listed times and amounts of feed eaten by individual sows at an ESF station. Most sows ate their daily allotment in a single trip to the feeder. However, occasionally a sow consumed her feed over multiple visits. The time of record in these rare cases was the feeding at which she consumed the largest portion of her daily ration. A feed rank (FR) was determined for each sow over a week period by taking the average daily feed order over the 7-day period preceding a Wednesday behavioral observation day. It was possible for sows to have fewer than seven observations for feed order over a 7-day period, as some animals may have missed an occasional meal or because of movement of animals in and out of the pen. In approximately 99% of sows in each pen, five observations were used for the weekly feed-rank calculations. It was not possible to retroactively capture the feed-order data prior to the first day of data collection, and thus feed rank was calculated only for the second and third days of data collection. Accordingly, feed-rank correlations were limited to the final 2 days of behavioral observations.

**Figure 1:** Schematic of sow gestation area on study farm and placement of ropes for collection of oral fluids. Study Farm 1 was a farrow-to-wean sow farm where gestating sows and gilts were housed in pre-implantation, dynamic groups. Animals were fed via electronic sow feeding stations (ESFs). Gilts were housed separately from older parity sows. Each sow gestated in one of two pens that each contained three ESF stations. The flooring was totally slatted except for the 2.10 × 3.35-meter sleeping areas in each pen that had raised, solid concrete bases (stippled areas). The gestation area included three 1.8 × 2.1-meter boar pens (BP) that could be used for automated heat detection. Behavioral observations were carried out in both sow pens. Ropes were placed approximately 3 meters along the fence line from the feeder entrance (red squares). Sow interactions with the ropes were recorded by an individual with a handheld video camera outside the pen near each rope.



## Oral-fluid collection

**Farm 1.** Oral-fluid samples were collected for behavioral observations starting at approximately 8:00 AM and continuing for at least 55 minutes once a week on Wednesdays for 3 consecutive weeks. Cotton ropes, 1.6 cm in diameter (Troyer's Rope Co, Conneautville, Pennsylvania), were tied to the fence-line of the pen, single or paired, 3 meters from the feeder entrance (Figure 1), at a height of 1 meter from the floor, leaving approximately 0.5 meter of rope exposed to the sows in the pen.<sup>16</sup> Single ropes were hung alone, whereas paired ropes were hung 0.75 meter apart in the same location. Oral fluids collected on Day 1 were submitted for PRRS antibody testing. Oral fluids were harvested by gathering the rope in a plastic bag, grasping the rope, and pulling it from the bag.

**Farm 2.** Oral fluids were also collected on Farm 2, which had historically tested PRRS-positive. A single 1.6-cm diameter cotton rope was placed approximately 3 meters from the entrance of a feeder in each of three different pens at approximately 8:00 AM and collected 1 hour later. Individual sows contacting the rope during this hour were identified for subsequent serological testing. Oral fluids were harvested as described for Farm 1.

## Serological data collection

**Farm 1.** For comparison with oral-fluid samples, blood was collected on Day 2 from 17 sows that were verified by video to have chewed on the rope from which oral fluids had been collected on Day 1. Blood samples were collected from restrained sows via venipuncture of the anterior vena cava.

**Farm 2.** Sows that chewed on the ropes were marked by an observer. Ten of the marked sows from each rope were then restrained and blood samples were collected as described for Study Farm 1.

## Laboratory testing

All blood samples were tested with the Idexx PRRS enzyme-linked immunosorbent assay (ELISA) X3 Ab test (Idexx Laboratories, Inc, Westbrook, Maine), and oral-fluid samples were tested by Idexx PRRS Oral Fluids Ab test (Idexx Laboratories, Inc) at the Iowa State University Veterinary Diagnostic Laboratory. All oral-fluid and serum samples were maintained on ice from collection until receipt at the laboratory. Samples were tested individually and the resulting sample-to-positive (S:P) ratios scored as positive or negative, with an S:P ratio of  $\geq 0.4$  considered positive.

## Statistical evaluation

Data analysis was performed using STATA version 13.1 (StataCorp LP, College Station, Texas). According to the Shapiro Wilk test, NSC and NAE were normally distributed and thus these data were analyzed using a two-way analysis of variance (ANOVA) with sampling day (DAY) and number of ropes (ROPES) as main effects. A Kruskal-Wallis test was used to test similar relationships for TFC, which was not normally distributed. Spearman's correlation test was used to examine correlations between continuous variables (oral-fluids ELISA and serological ELISA), and a point biserial correlation test was employed for correlations involving binary data (initiate aggression, "yes" or "no;" chew, "yes" or "no"). Normally distributed behavioral data are presented either as a daily mean, which represents the mean value of all replicates on that day, or as an overall mean with the standard error of the mean (SEM), which is the mean value for all replicates in the study. For the variables that were not normally distributed, behavioral data are presented as the median value for each day or as an overall median with the interquartile range (IQR), which represents the median value across all replicates in the study. Only significant interactions are reported. As location was not varied as part of the study design, the location of the ropes was not analyzed.

## Results

### Number of sows to chew

The overall average NSC at a rope site was  $19.9 \pm 1.2$  (Table 1). Number of sows to chew increased numerically from a mean of 15.7 to 21.7 over the 3 days of collection, but DAY did not significantly influence NSC ( $P > .05$ ) (Table 1). ROPES also did not influence NSC ( $P > .05$ ).

### Time to first chew

The range of time to first chew (TFC) across all replicates was 0.01 to 1367.04 seconds, with a median of  $43.7 \pm 345.7$  seconds. ROPES did not influence TFC ( $P > .05$ ), but there was a significant effect of DAY on TFC (Table 1; Kruskal-Wallis;  $P < .05$ ). Sows initially approached the rope more than 20 times faster on day 3 than on day 1 ( $P < .01$ ), as both median time to first chew and the IQR decreased with repeated rope sampling in the pen (Figure 2).

### Number of aggressive events

The overall average NAE in the 55 minutes analyzed was  $29.7 \pm 4.5$  (Table 1). The two-way

ANOVA showed there was a significant effect of DAY on NAE ( $P < .05$ ), as they doubled between day 1 and day 3. ROPES did not influence NAE ( $P > .05$ ).

### Feed rank

On sampling day 2, sows that ate later in the day (lower FR) were more likely to chew on a rope (correlation [ $r$ ] = 0.15;  $P < .01$ ), and of the sows that chewed on a rope, those with a higher FR were more likely to initiate aggression at the rope ( $r = -0.34$ ;  $P < .05$ ). The same results were repeated on sampling day 3, where sows with a lower FR were more likely to chew on a rope ( $r = 0.16$ ;  $P < .01$ ), but of the sows chewing on a rope, the ones with higher FR were more likely to initiate aggression ( $r = -0.43$ ;  $P < .01$ ).

### Serology

The pen-level oral-fluid ELISA result was indicative of the individual sow serum ELISA findings. The pen-based oral-fluid samples were PRRS-positive when there were serologically PRRS-positive sows in the pen that had sampled the rope (Table 2). Furthermore, the magnitude of the oral-fluid ELISA S:P ratio was positively correlated with the serum ELISA S:P ratio of sows that had chewed on the rope and were sampled for serological testing ( $r = 0.79$ ;  $P < .001$ ). Finally, the S:P ratios for oral-fluid ELISAs on samples collected from individual ropes increased numerically as the average serum S:P ratios of a subset of the sows that sampled the rope increased (Figure 3).

## Discussion

The work described here provides the first evidence to support the feasibility of oral-fluid collection for disease surveillance in group-housed gestating sows. On average, approximately 20 sows contacted a rope placed near the entrance of an ESF station. While the time for the first animal in the pen to chew on the rope decreased and the number of aggressive events at the rope increased following weekly sample collection, the total number of sows contributing to an oral-fluid sample did not change, given repeated exposure to the rope. Interestingly, the number of aggressive events at the rope correlated with feed rank, a proxy for social hierarchy.<sup>11,12</sup> Dominant animals were more likely to be involved in fights at the rope, but, perhaps counter intuitively, animals with a lower social status were more likely to sample the rope. Finally, the mean serum S:P



**Table 1:** Behavioral observations of sows interacting with ropes used for oral-fluid collection (Farm 1)\*

| Day | n  | Mean no. of sows to chew | Median time to first chew (seconds) | Mean no. of aggressive events |
|-----|----|--------------------------|-------------------------------------|-------------------------------|
| 1   | 3  | 15.7                     | 558.0 <sup>a</sup>                  | 14.3 <sup>c</sup>             |
| 2   | 4  | 20.5                     | 174.4                               | 28.0                          |
| 3   | 6  | 21.7                     | 24.7 <sup>b</sup>                   | 38.5 <sup>d</sup>             |
| All | 13 | 19.9                     | 234.1                               | 29.7                          |

\* Study described in Figure 1. Mean number of sows to chew, median time to first chew, and mean number of aggressive events are summarized for the 55 minutes of video data on different experimental days; n is the number of experimental replications on each day.

<sup>a,b</sup> Values with different superscripts within a column are significantly different within the main effect ( $P < .01$ ; two-way ANOVA with DAY and ROPES as main effects).

<sup>c,d</sup> Values with different superscripts within a column are significantly different within the main effect ( $P < .05$ ; two-way ANOVA with DAY and ROPES as main effects).

DAY = sampling day; ROPES = number of ropes (one or two)

ratios correlated with the S:P ratios of the pen-level oral-fluid samples.

Our findings on the number of animals to sample the rope support this technique as a possible sampling protocol for dynamic pre-implantation groups like those in the farms studied here. The placement of ropes approximately 3 meters from the entrances of two to four different feeders is predicted to generate samples that would contain oral fluids from 30 or more different sows in the barn. There are, however, many different options available for group housing gestating sows, and further work will be needed to understand how generally applicable these findings are to other types of gestational group housing.

The time of day that the ropes are placed in the pen is likely to impact the outcome of sampling, given that the activity level of sows in an ESF pen is not constant across the day. From the time the feeding system turns on, activity increases over an 8- to 12-hour period and then starts to decrease as the majority of the animals are fed and the stations close for the day.<sup>17,18</sup> In this study, the optimal time of day to sample was not investigated specifically, but sampling time was chosen on the basis of our previous research and clinical experience with group-housed sows being fed by ESF. Our goal was to place the ropes more or less halfway through their daily feeding cycle, while the feeders were still open and the sows were still eating. The start of the feeding cycle varies from farm to farm, and accordingly, the absolute time for sampling may be farm-specific. However, we

suggest that determining the sampling time relative to the start and finish times of the feeding cycle is an important consideration, especially when sampling in dynamic pre-implantation groups fed by ESF, to ensure that sows are still active and feeding when investigators are attempting to sample.

Our studies revealed that the TFC in a pen decreased with subsequent rope sampling in the pen; however, the overall number of sows to chew was not affected by sampling history. A similar effect on experience was reported for rope testing of individually housed sows. Pepin et al<sup>7</sup> report an increase in the number of sows successfully sampled with repeated exposure to rope testing, but did not study whether the latency of animals that chewed on a rope depended on experience. The practical implication for the TFC on repeated sampling is that when sampling for the first time in a pen, oral-fluid collection may take longer (median difference in TFC of approximately 9 minutes). The range of time it took for sows to approach the rope is important as well, because producers and veterinarians should not be discouraged if it takes over 20 minutes for the sows to approach the rope the first time sampling is attempted.

Sows that had a lower feed rank (ie, sows that ate later in the day relative to other sows) chewed on a rope more often. One interpretation of these findings is that frequency of rope chewing is inversely correlated with social status. However, alternatively, we would suggest that these observations are more likely explained by the time of sampling co-

ordinating with the time of feeding of these sows. Thus, the timing of rope placement likely will impact the part of the social hierarchy that is captured by the oral-fluid sampling, and placing the ropes at a point earlier in the feeding cycle may sample sows with a higher feed rank and associated higher social status.<sup>11,12</sup>


Aggressive events at the rope exhibited a positive correlation with repeated oral-fluid collection in the pen, as well as social hierarchy. However, neither impacted the total number of sows to interact with the rope. It is interesting that, despite this increase in aggressive events at the rope, these aggressive events do not limit the number of sows sampling the rope, ie, dominant sows are not successful in guarding the ropes.

We observed a correlation between the oral-fluid PRRS ELISA S:P ratios and the serum S:P ratios of a subset of sows that chewed on the rope. Even when only 30% of the blood-tested sows contributing to the rope sample were seropositive on PRRS ELISA, the oral-fluid sample was positive on PRRS ELISA. The exact contribution that a given sow makes to the oral-fluid sample will depend on her serum S:P ratio and the amount of saliva she contributes to the sample. The results show that the magnitude of the oral-fluid S:P ratio was better correlated with the maximum value of an individual sow's S:P ratio than with the number of seropositive sows or the mean S:P ratio of the blood-sampled sows at the rope. These findings highlight that the oral-fluid sample S:P ratios are useful for PRRS surveillance at the herd level, but their interpretation is likely more complicated than the simple arithmetic mean of individual serum S:P ratios.

This study documents that it is possible to collect oral fluids from group-housed sows, as reported for individually housed boars<sup>6</sup> or sows.<sup>7</sup> Our findings on sows housed in pre-implantation dynamic groups suggests that collecting and testing oral-fluid samples could be an effective and sensitive method for exposure screening for pathogens with validated oral-fluid diagnostic tests. It also highlights how more work is needed to understand the limitations of this approach in herds with low prevalence of seropositive animals or in other types of group-housing systems. Further work is also needed to investigate how disease presence may alter both sow behavior and social structure, as well as potentially influence the specific animals that interact with the rope.



**Figure 2:** Study described in Figure 1. The duration of time required for the initial animal to chew on a rope (TFC) decreased with repeated sampling of group-housed gestating sows. Boxplot demonstrates that both the median TFC, as well as the interquartile range, decreased with repeated sampling. Time points marked by an asterisk differ significantly (Kruskal-Wallis;  $P < .01$ ).



## Implications

- Rope sampling will likely provide a method for readily collecting oral-fluid samples from sows housed in dynamic groups and fed with an electronic sow feeder.
- The subset of sows sampled from the pen will most likely depend on the point during the course of the daily feeding cycle when ropes are hung, as sows interacting with the rope likely correspond to those currently gathering to enter the ESF station to feed.
- The results of this study suggest that, under similar conditions, hanging two to four ropes per pen for approximately 1 hour, with each rope placed about 3 meters from the entrance of an ESF station, should capture an oral-fluid sample that represents 30 or more sows when at least two pens are sampled.

## Acknowledgements

This work was supported by Pennsylvania Pork Producers Council, Pennsylvania Soybean Growers Board, and USDA PRRS CAPII.

## Conflict of interest

None reported.

## Disclaimer

Scientific manuscripts published in the *Journal of Swine Health and Production* are peer reviewed. However, information on medications, feed, and management techniques may be specific to the research or commercial situation presented in the manuscript. It is the responsibility of the reader to use information responsibly and in accordance with the rules and regulations governing research or the practice of veterinary medicine in their country or region.

## References

1. Corthier G. Swine Fever: influence of passive immunity on pig immune response following vaccination with a live virus vaccine (Thiverval strain). *Annales de Recherches Vétérinaires [Annals of Veterinary Research]*. 1976;7:361–372.
2. Prickett J, Zimmerman J. The development of oral fluid based diagnostics and applications in veterinary medicine. *Anim Health Res Rev*. 2010;11:207–216.
3. Prickett JR, Kim W, Simer R, Yoon K, Zimmerman J. Oral-fluid samples for surveillance of commercial growing pigs for porcine reproductive and respiratory syndrome virus and porcine circovirus type 2 infections. *J Swine Health Prod*. 2008;16:86–91.

\*4. Spronk G, Nerem J, Hanson D, Wayne S, Dee S. Oral fluids as an alternative technology in practice. *Proc Iowa Dis Conf*. 2011;127–131.

\*5. Day D, Baysinger A, Hartsook G. PRRS Diagnostics: correlation of serum, tonsil scrapings, and oral fluids in gilts with natural exposure. *Proc AASV*. Phoenix, Arizona. 2011:81–82.

6. Kittawornrat A, Prickett J, Chittick W, Wanga C, Engle M, Johnson J, Patnayak D, Schwartz T, Whitney D, Olsena C, Schwartz K, Zimmerman J. Porcine reproductive and respiratory syndrome virus (PRRSV) in serum and oral fluid samples from individual boars: Will oral fluid replace serum for PRRSV surveillance? *Virus Res*. 2010;154:170–176.

7. Pepin B, Fanfang L, Main R, Ramirez A, Zimmerman J. Collection of oral fluids from individually housed sows. *J Swine Health Prod*. 2015;23:35–37.

8. Elmore M, Garner J, Johnson A, Kirkden R, Richert B, Pajor E. Getting around social status: Motivation and enrichment use of dominant and subordinate sows in a group setting. *Appl Anim Behav Sci*. 2011;133:154–163.

9. Seddon Y, Guy J, Edwards SA. Optimising oral fluid collection from groups of pigs: Effect of housing system and provision of ropes. *Vet J*. 2012;193:180–184.

10. Jensen P. An analysis of agonistic interaction patterns in group-housed dry sows: Aggression regulation through an “avoidance order.” *App Anim Ethol*. 1982;9:47–61.

11. Chapinal N, Ruiz-de-la-Torre J, Cerisuelo A, Baucells M, Gasa J, Manteca X. Feeder use patterns in group-housed pregnant sows fed with an unprotected electronic sow feeder (Fitmix). *J Appl Anim Welf Sci*. 2008;11:319–336.

12. Hunter E, Broom D, Edwards S, Sibly S. Social hierarchy and feeder access in a group of 20 sows using a computer-controlled feeder. *Anim Prod*. 1988;47:139–148.

13. Tuchscherer M, Puppe B, Tuchscherer A, Kanitz E. Effects of social status after mixing on immune, metabolic, and endocrine responses in pigs. *Phys Behav*. 1998;64:353–360.

14. Bench CJ, Rioja-Lang FC, Hayne SM, Gon-you HW. Group gestation housing with individual feeding – I: How feeding regime, resource allocation, and genetic factors affect sow welfare. *Livest Sci*. 2013;1522: 208–217.

\*15. Parsons T. Making electronic sow feeding work in the United States: Static versus dynamic animal flows. *Proc Lemna Conf*. 2011:203–205.

16. Prickett J, Johnson J. Prognostic profiling of swine populations using oral fluid samples. Veterinary Diagnostic Laboratory, Iowa State University, Ames, Iowa. Available at <https://vetmed.iastate.edu/vdpam/research/disease-topics/swine/oral-fluids>. Accessed 26 May 2016.

\*17. Pavlovic L, Dunipace S, Horback T, Parsons T. Behavioral assessment of gestating sows via ear-mounted accelerometers. *Proc AASV*. Dallas, Texas. 2014:353.

\*18. Sullivan K, Parsons T. Evaluation of sleep-wake cycle and behavioral indicators of REM in gestating sows. *Proc AASV*. Orlando, Florida. 2013:285.


\*Non-refereed references.

**Table 2:** Proportion of sows seropositive for PRRS and comparison of S:P ratios for serum and oral-fluid samples\*

| Farm | No. of serum samples | No. (proportion) of positive serum samples | Mean serum S:P ratio (range) | Mean oral-fluid S:P ratio |
|------|----------------------|--|------------------------------|---------------------------|
| 1    | 17                   | 0 (0)                                      | 0.013 (0.0 - 0.051)          | 0.038                     |
| 2    | 10                   | 8 (0.8)                                    | 1.206 (0.086 - 3.064)        | 3.985                     |
| 2    | 10                   | 3 (0.3)                                    | 0.580 (0.093 - 2.039)        | 1.859                     |
| 2    | 10                   | 10 (0.1)                                   | 1.693 (0.53 - 2.874)         | 3.370                     |

\* Study described in Figure 1. Blood samples were collected from sows that chewed on the ropes. Serum samples were tested with the PRRS X3 Ab ELISA (Idexx Laboratories, Inc, Westbrook, Maine) and oral-fluid samples were tested by PRRS Oral Fluids Ab ELISA (Idexx Laboratories, Inc). An S:P ratio  $\geq 0.4$  was considered positive. PRRS = porcine reproductive and respiratory syndrome; S:P = sample-to-positive ratio; ELISA = enzyme-linked immunosorbent assay.

**Figure 3:** Study described in Figure 1. Blood samples and oral fluids were collected from a subset of 10 sows for testing using an enzyme-linked immunosorbent assay (ELISA): the PRRS X3 Ab ELISA for serum (Idexx Laboratories, Inc, Westbrook, Maine), and the PRRS X3 Oral Fluids ELISA for oral-fluid samples (Idexx Laboratories, Inc). Oral-fluid average sample-to-positive (S:P) ratio increased as the average S:P ratio of serum from sows that interacted with the rope increased. The average S:P ratio of the subset of sows that were marked as chewing on the rope is plotted against the average oral-fluid ELISA S:P ratio for pairs of ropes hung in four different pens. The line highlights the relationship between individual serum ELISA values and the ELISA values for the collective oral-fluid samples obtained from these same group-housed sows (linear fit described by  $y = 3.78 \times - 0.0015$ ,  $R^2 = 0.83$ ).



# Antimicrobial resistance and virulence factors of *Streptococcus suis* strains isolated from diseased pigs in southern Italy (Sardinia)

Maria T. Tedde, MS; Cristian Pilo, MS, DVM; Marina Frongia, BA; Germano Orrù, PhD; Claudio Ruggeri, PhD; Manuel Liciardi, MS, DVM

## Summary

*Streptococcus suis* is a major swine pathogen responsible for important economic losses to the porcine industry worldwide. The objective of this study was to characterize strains of *S suis* isolated from dead piglets from farms located in southern Italy (Sardinia) between 2012 and 2014, by determining their genotype profiles, antimicrobial resistance profiles, and presence of associated virulence factors in order to evaluate a potential association between antimicrobial resistance serotypes and virulence factors. A total of

39 *S suis* isolates were examined for possession of virulence-associated factors using multiplex polymerase chain reaction assays. All isolates were tested for susceptibility to antimicrobial agents. Fisher's exact test was performed in order to study the correlation between antimicrobial resistance and virulence factors *epf*+/*epf*-. Genotypes *cps2*+/*epf*+/*sly*+/*mrp*+/*arcA*+, *cps2*+/*epf*-/*sly*+/*mrp*+/*arcA*+, and *cps2*-/*epf*-/*sly*+/*mrp*+/*arcA*+ were identified, representing 18.0%, 74.6%, and 7.4% of the isolates, respectively. A high frequency of resistance was observed

for tetracycline (88.9%) and erythromycin (38.9%). No correlation between the virulence factor *epf* and resistance to multiple antibiotics was found.

**Keywords:** swine, *Streptococcus suis*, multiplex polymerase chain reaction, virulence factor, antimicrobial susceptibility

**Received:** July 28, 2015

**Accepted:** February 18, 2016

## Resumen - Resistencia antimicrobiana y factores de virulencia de las cepas aisladas del *Streptococcus suis* de cerdos muertos en el sur de Italia (Sardinia)

El *Streptococcus suis* es un importante patógeno porcino responsable de relevantes pérdidas económicas a la industria porcina mundialmente. El objetivo de este estudio fue clasificar cepas de *S suis* aisladas de lechones muertos de granjas localizadas en el sur de Italia (Sardinia) entre 2012 y 2014, por medio de la determinación de los perfiles de su genotipo, perfiles de su resistencia antimicrobiana, y la presencia de factores de virulencia relacionados para evaluar la asociación potencial entre estereotipos de resistencia

antimicrobiana y factores de virulencia. Se examinaron un total de 39 *S suis* aislados en busca de la posesión de factores de virulencia asociados utilizando múltiples pruebas de reacción en cadena de polimerasa. Se analizaron todos los aislados en busca de susceptibilidad a agentes antimicrobianos. Se realizó la prueba exacta de Fisher para estudiar la correlación entre la resistencia antibacteriana y los factores de virulencia *epf*+/*epf*-. Se identificaron los genotipos *cps2*+/*epf*+/*sly*+/*mrp*+/*arcA*+, *cps2*+/*epf*-/*sly*+/*mrp*+/*arcA*+, y *cps2*-/*epf*-/*sly*+/*mrp*+/*arcA*+, representando 18.0%, 74.6%, y 7.4% de los aislados, respectivamente. Se observó una alta frecuencia de resistencia a la tetraciclina (88.9%) y eritromicina (38.9%).

No se encontró correlación entre el factor de virulencia *epf* y la resistencia a múltiples antibióticos.

## Résumé - Antibiorésistance et facteurs de résistance de souches de *Streptococcus suis* isolées de porcs malades en Italie du sud (Sardaigne)

*Streptococcus suis* est un agent pathogène majeur du porc responsable d'importantes pertes économiques dans l'industrie porcine à l'échelle mondiale. L'objectif de la présente étude était de caractériser des souches de *S suis* isolées de porcelets morts provenant de fermes localisées en Italie du sud (Sardaigne) entre 2012 et 2014, en déterminant les profils génotypiques, les profils d'antibiorésistance, et la présence de facteurs de virulence afin d'évaluer l'association potentielle entre l'antibiorésistance et les facteurs de virulence. Trente-neuf isolats de *S suis* ont été examinés pour la présence de facteurs de virulence par épreuves d'amplification en chaîne par la polymérase multiplex. Tous les isolats ont été testés pour leur sensibilité à différents agents antimicrobiens. Le test exact de Fisher a été utilisé afin d'étudier la corrélation entre l'antibiorésistance et les facteurs de virulence *epf*+/*epf*-. Les génotypes *cps2*+/*epf*+/*sly*+/*mrp*+/*arcA*+, *cps2*+/*epf*-/*sly*+/*mrp*+/*arcA*+, *cps2*-/*epf*-/*sly*+/*mrp*+/*arcA*+,

MTT, CP, MF, ML: S. C. Diagnostica Territoriale di Cagliari, Istituto Zooprofilattico Sperimentale della Sardegna "G. Pegreff", Elmas, CA, Italy.

GO: IDNA Sequencing Service (DSS), University of Cagliari, Italy.

CR: Department of Biomedical Science, University of Cagliari, Italy.

**Corresponding author:** Dr Maria Tania Tedde, S. C. Diagnostica Territoriale di Cagliari, Istituto Zooprofilattico Sperimentale della Sardegna "G. Pegreff," Via dell' Acquedotto Romano, Zona Industriale Est, 09030, Elmas, CA, Italy; Tel: + 39 070 21914230; Fax: +39 070 2135121; E-mail: [tedde.tania@gmail.com](mailto:tedde.tania@gmail.com).

This article is available online at <http://www.aasv.org/shap.html>.

Tedde MT, Pilo C, Frongia M, et al. Antimicrobial resistance and virulence factors of *Streptococcus suis* strains isolated from diseased pigs in southern Italy (Sardinia). *J Swine Health Prod.* 2016;24(5):253–258.



et *cps2*-/*epf*-/*sly*+/*mrp*+/*arcA*+ ont été identifiés, représentant respectivement 18,0%, 74,6%, et 7,4% des isolats. On nota une fréquence élevée de résistance à la tétracycline (88,9%) et à l'érythromycine (38,9%). Aucune corrélation entre le facteur de virulence *epf* et une antibiorésistance multiple n'a été notée.

**S***treptococcus suis* infection is considered a major problem worldwide in the swine industry, resulting in great economic losses.<sup>1</sup> Pigs may acquire *S suis* via both vertical and horizontal transmission. Colonized animals typically harbor the organism in their tonsils and may never develop disease (carrier animals). On the contrary, some carrier piglets eventually develop bacteremia, septicemia, meningitis, or all three, due to dissemination of *S suis* from tonsils or other mucosal surfaces or both, usually when maternal antibodies decline.<sup>2</sup> Of the various manifestations of the disease, septicemia and meningitis are by far the most striking, but endocarditis, pneumonia, and arthritis may also be observed. Nevertheless, in hyperacute cases of infection, pigs are often found dead with no premonitory signs of disease.<sup>3</sup> Moreover, *S suis* has zoonotic potential, causing septicemia with or without septic shock, meningitis, and other less common infections in humans.<sup>4</sup> Human infection with *S suis* has become a serious zoonosis and has been observed in many countries where intensive swine production is practised.<sup>2,5</sup> Overall, three human cases of *S suis* meningitis have been reported in Italy, one in the 1990s and two in 2007. One of the two cases reported in 2007 was identified in the geographical area covered by this study and was characterized as *S suis* serotype 2.<sup>6,7</sup> A total of 35 serotypes of *S suis* have been described and defined on the basis of the antigenicity of their capsular polysaccharide (CPS).<sup>8</sup> *Streptococcus suis* strains differ in virulence, and strains of the same serotype can be differentiated by the expression of virulence-associated factors, including muramidase-released protein (MRP, encoded by *mrp*); a peptidoglycan-associated protein probably acting as an adhesin; an extracellular protein factor (EF, encoded by *epf*); and sulilysin (SLY, encoded by *sly*), which is a thiol-activated hemolysin with a cytotoxic effect that might allow penetration into deeper tissues.<sup>9</sup> Muramidase-released protein, EF, and SLY have been considered the major virulence-associated markers of

*S suis* 2,<sup>10</sup> and the arginine deiminase enzyme (ADS, encoded by *arcA*) has been recently described<sup>11</sup> and seems to play an important role in survival of the bacterium by increasing resistance to acidity. The gene *cps2* is specific for *S suis* serotypes 2 and 1/2 and is considered a fifth virulence factor.<sup>12</sup> The virulence factors MRP, EF, and SLY are associated with *S suis* serotype 2 strains in Europe and Asia, but not with the less virulent North American strains.<sup>12</sup> The efficacy of many commercially available *S suis* killed whole-cell vaccines is poor because protection is limited to homologous strains.<sup>13</sup> Previous studies revealed a wide diversity of antimicrobial resistance and varied distribution of virulence-associated factors in different serotypes of *S suis*, but few studies have focused on the relationship between antimicrobial resistance and virulence factors.<sup>14-17</sup> To our knowledge, this study represents the first characterization of clinical strains of *S suis* isolated from dead piglets from farms located in southern Italy (Sardinia) between 2012 and 2014. Hence, the objective of this work was to determine the antimicrobial resistance, serotypes, and virulence factors of these clinical isolates in order to estimate a correlation among these three characteristics.

## Materials and methods

This study did not require ethical review because the activities comprised a part of a periodic, routine diagnostic monitoring program and did not involve animal experimentation.

### Bacterial strains and culture conditions

In this study, 39 strains of *S suis* were recovered from pigs at necropsy at the Istituto Zooprofilattico Sperimentale della Sardegna "G. Pegreff" (Public Veterinary Diagnostic Laboratory, Sardinia, Italy) between 2012 and 2014 from samples submitted for disease diagnosis in piglets from farms located in southern Italy (Sardinia). The samples were collected from a variety of tissues from dead pigs with lesions such as pneumonia or pleurisy or both, meningitis, endocarditis, and septicemia. *Streptococcus suis* strains were isolated frequently from pigs between 5 and 10 weeks of age. The bacterial strains were identified as *S suis* by cultural methods. Specimens were inoculated onto Columbia agar plates (Oxoid Ltd, Basingstoke, United Kingdom) supplemented with 5% sheep blood and incubated in aerobic conditions at 37°C for 24 to 48 hours. Two to three colonies that did

not exceed 1 mm in diameter and exhibited  $\alpha$ -hemolysis were picked from each plate to subculture on Columbia 5% blood agar plates and were incubated in the same manner. Suspicious colonies, ie, gram-positive cocci negative on the catalase test, were confirmed by the API-20STREP system (BioMérieux, Marcy l'Etoile, France).

### DNA extraction and PCR conditions

Genomic DNA was isolated and purified with the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) using the method for gram-positive microorganisms indicated in the manufacturer's instructions. Genomic DNA was stored at -20°C until further processing. Multiplex PCR (mPCR)<sup>18</sup> was used to determine the presence of *cps2*, *epf*, *sly*, *mrp*, and *arcA* genes. In order to evaluate the sensitivity of the mPCR assays, *S suis* type strain DSMZ 9682 was used as a reference strain. The sequences of oligonucleotidic primers are listed in Table 1. The mPCR mixture contained PCR buffer IX (Invitrogen, Cergy Pontoise, France), 2 mM MgCl<sub>2</sub> (Invitrogen); a 300- $\mu$ M concentration of each of deoxynucleoside triphosphate (Invitrogen), 0.1  $\mu$ M of each primer for *epf*, 0.06  $\mu$ M of each primer for *cps2*, 0.03  $\mu$ M of each primer for *sly*, 0.05  $\mu$ M of each primer for *mrp*, and 0.06  $\mu$ M of each primer for *arcA*; 0.04 U of *Taq* DNA polymerase (Invitrogen); and 50 ng of DNA template. UltraPure DNase/RNase-Free Distilled Water (Thermo Fisher Scientific, Waltham, Massachusetts) was used as negative control. The reaction procedure consisted of an initial denaturation at 94°C for 2 minutes, 40 cycles at 94°C for 60 seconds, 55°C for 60 seconds, and 72°C for 90 seconds, with a final extension at 72°C for 5 minutes. The amplified products were separated in a 2% agarose gel in Tris-acetate-EDTA (TAE) buffer (Thermo Fisher Scientific) for 1 hour at a constant voltage of 125 V. Amplified products were stained with Syber Safe (Thermo Fisher Scientific) and detected by ultraviolet transillumination. The 100 bp Smart Ladder (Invitrogen) was used as a molecular size standard.

### Antimicrobial susceptibility testing

The 36 strains determined to be *S suis* *cps2*+ were tested for susceptibility to nine antimicrobials according to the Clinical and Laboratory Standards Institute (CLSI)

**Table 1:** Polymerase chain reaction primers used to amplify virulence genes of *Streptococcus suis* strains\*

| Gene        | GenBank accession number | Primer sequence (5 <sup>^</sup> -3 <sup>^</sup> ) | Position in coding sequence |
|-------------|--------------------------|---|-----------------------------|
| <i>epf</i>  | X71881                   | 5'-CGC AGA CAA CGA AAG ATT GA-3'                  | 744 bp                      |
|             |                          | 5'-AAG AAT GTC TTT GGC GAT GG-3'                  |                             |
| <i>cps2</i> | AF118389                 | 5'-TTT GTC GGG AGG GTT ACT TG-3'                  | 498 bp                      |
|             |                          | 5'-TTT GTC GGG AGG GTT ACT TG-3'                  |                             |
| <i>mrp</i>  | X64450                   | 5'-ATT GCT CCA CAA GAG GAT GG-3'                  | 188 bp                      |
|             |                          | 5'-TGA GCT TTA CCT GAA GCG GT-3'                  |                             |
| <i>sly</i>  | Z36907                   | 5'-GCT TGA CTT ACG AGC CAC AA-3'                  | 248 bp                      |
|             |                          | 5'-CCG CGC AAT ACT GAT AAG C-3'                   |                             |
| <i>arcA</i> | AF546864                 | 5'-TGA TAT GGT TGC TGC TGG TC-3'                  | 118 bp                      |
|             |                          | 5'-GGA CTC GAG GAT AGC ATT GG-3'                  |                             |

\* Between 2012 and 2014, thirty-nine *S suis* strains were isolated from dead piglets from farms located in southern Italy (Sardinia). Strains were examined for possession of virulence-associated factors using multiplex polymerase chain reaction.

2013 guidelines.<sup>19</sup> Three to four colonies from an overnight culture on Columbia agar supplemented with 5% sheep blood were suspended in Mueller Hinton (MH) broth (Becton Dickinson, Pont de Claix, France). The suspension was adjusted to a 0.5 McFarland standard and diluted to obtain an inoculum of 10<sup>6</sup> colony-forming units (CFU) per mL of *S suis*. For each isolate, two plates were inoculated by flooding MH agar supplemented with 5% sheep blood with the diluted suspension (4 mm depth) (Becton Dickinson). The antibiotic discs were placed with a disc dispenser (Bio-Rad, Hercules, California), and plates were incubated at 37°C for 18 hours. Antimicrobial agents tested were as follows: amoxicillin (10 µg per disc), amoxicillin-clavulanic acid (30 µg per disc), penicillin G (10 units per disc), ampicillin (10 µg per disc), ceftiofur (30 µg per disc), enrofloxacin (5 µg per disc), tetracycline (30 µg per disc), trimethoprim-sulfamethoxazole (25 µg per disc) (Oxoid Ltd), and erythromycin (15 µg per disc) (Cefar Diagnóstica Ltda, São Paulo, Brazil). *Escherichia coli* ATCC 25922, *E coli* ATCC 35218, and *Enterococcus faecalis* ATCC 29212 were used as control strains. The zone of growth inhibition was interpreted as sensitive, intermediate, or resistant. The inhibition zone diameters of *S suis* strains and the reference strains were measured on the same day using a sliding caliper. For amoxicillin, amoxicillin-clavulanic acid, ceftiofur, erythromycin, penicillin G, and trimethoprim-sulfamethoxazole, disc diffusion susceptibility was tested according to the

Clinical and Laboratory Standards Institute (Approved Standard VET01-A4; CLSI, 2013) guidelines specific for *S suis* strains.<sup>19</sup> For ampicillin, enrofloxacin, and tetracycline, specific breakpoints for *S suis* are not available in CLSI guidelines. For those antimicrobials, interpretation of disc diffusion susceptibility was evaluated according to breakpoints indicated by the manufacturer as specific for *Streptococcus* species (Oxoid Ltd).

### Statistical analysis

The correlation between antimicrobial resistance and virulence factors was studied. Microbial resistance values were expressed as percentages and compared using a Fisher's exact test. Statistical analysis was performed with SPSS software (version 15.0; SPSS Inc, Chicago, Illinois), and statistical significance was defined at  $P < .05$ .

### Results

All isolates were determined to be *S suis* serotype 2 by biochemical characteristics (API -20 strep, BioMerieux SA France) and further confirmed by positive PCR for the genes coding for the 16S rRNA of *S suis* and for the capsule of *S suis* serotype 2 (*cps2+*).

In this study, 39 *S suis* strains were isolated, and 36 of them (92.3%) belonged to genotype 2 (*cps2+*). Among the 39 cases, 38.5% were categorized as lung infections, 18.0% as meningitis, 18.0% as endocarditis, and 25.5% as septicemia (cases where *S suis* was isolated from multiple organs or from mediastinal lymph nodes, spleen, liver, and kidney were

classified as septicemia) (Table 2). Numbers of isolates from various organs are shown in Table 3. Virulence factor gene *epf* was detected in 18.0% of the isolates, whereas virulence factor genes *sly*, *mrp*, and *arcA* were detected in 100% of the isolates. Three genotypes, *cps2+/epf+/sly+/mrp+/arcA+*, *cps2+/epf-/sly+/mrp+/arcA+*, and *cps2-/epf-/sly+/mrp+/arcA+* were identified, representing 18.0%, 74.6%, and 7.4%, of the isolates respectively (Table 3).

The collection of 36 *S suis cps2+* strains was tested for susceptibility to nine antimicrobials (Table 4). A high frequency of resistance was observed for tetracycline (88.9%), erythromycin (38.9%), trimethoprim-sulfamethoxazole (16.7%), and enrofloxacin (11.1%). Multiple antimicrobial resistance (two or more antimicrobials) was observed in 58.3% of the *S suis* isolates. Sensitivity testing showed that ampicillin had the greatest antimicrobial effect on the 36 isolates (100% of strains were susceptible), followed by amoxicillin, amoxicillin-clavulanic acid, penicillin G, and ceftiofur (Table 4).

The correlation between antimicrobial resistance and virulence factors *epf+/epf-* was evaluated (Table 5). The virulence factors *cps2+/cps2-* were not analyzed for any correlation with antimicrobial resistance because of the small number of *cps2-* strains. (Table 2). Since no strains resistant to ampicillin were found, no correlation data were collected for this antibiotic. The virulence factor *epf* was not correlated with resistance to multiple antibiotics in this study.

**Table 2:** Distribution of *Streptococcus suis* genotypes among diseased pigs\*

| Disease             | No. of isolates (%) | <i>Streptococcus suis</i> genotypes |                                    |                                    |
|---------------------|---------------------|-------------------------------------|------------------------------------|------------------------------------|
|                     |                     | <i>cps2+ /epf+/sly+/mrp+/arcA+</i>  | <i>cps2+ /epf-/sly+/mrp+/arcA+</i> | <i>cps2- /epf-/sly+/mrp+/arcA+</i> |
| Pneumonia/pleuritis | 15 (38.5)           | 5                                   | 10                                 | 0                                  |
| Meningitis          | 7 (18.0)            | 2                                   | 5                                  | 0                                  |
| Septicemia          | 10 (25.5)           | 0                                   | 9                                  | 1                                  |
| Endocarditis        | 7 (18.0)            | 0                                   | 5                                  | 2                                  |
| Total               | 39 (100.0)          | 7                                   | 29                                 | 3                                  |

\* Study described in Table 1.

**Table 3:** Number of *Streptococcus suis* genotypes isolated from organs of dead piglets\*

| Genotypes                         | Brain           | Spleen         | Heart           | Lung             | Liver          | Mediastinal LN  | Kidney         | Total isolates (%) |
|-----------------------------------|-----------------|----------------|-----------------|------------------|----------------|-----------------|----------------|--------------------|
| <i>cps2+/epf+/sly+/mrp+/arcA+</i> | 2               | 0              | 0               | 5                | 0              | 0               | 0              | 7 (18.0)           |
| <i>cps2+/epf-/sly+/mrp+/arcA+</i> | 5               | 2              | 5               | 10               | 2              | 4               | 1              | 29 (74.6)          |
| <i>cps2-/epf-/sly+/mrp+/arcA+</i> | 0               | 0              | 2               | 0                | 0              | 1               | 0              | 3 (7.4)            |
| <b>Total (%)</b>                  | <b>7 (18.0)</b> | <b>2 (5.1)</b> | <b>7 (18.0)</b> | <b>15 (38.5)</b> | <b>2 (5.1)</b> | <b>5 (12.8)</b> | <b>1 (2.5)</b> | <b>39 (100.0)</b>  |

\* Study described in Table 1.  
LN = lymph node.

## Discussion

*Streptococcus suis* is a major swine pathogen, responsible for important economic losses to the porcine industry worldwide. In western countries, *S suis* infections in humans have mostly been restricted to workers in close contact with pigs or swine by-products. However, in Southeast and East Asia, this bacterium also affects the general population and thus represents a significant public-health concern.<sup>2</sup> During the 3 years of monitoring, the organs of all piglets dead within the geographical district of interest were screened for *S suis* infection. *Streptococcus suis* strains isolated in this study represent the entire set of clinical strains whose infection led to piglet deaths. The number of isolates was small because this study focused attention on strains that cause piglet mortality. Strains were isolated from different farms; nevertheless, clonality among isolates cannot be excluded. The small number of studied strains and the potential for clonality can add bias to the evaluation of correlation between antimicrobial resistance and virulence factors.

An accurate isolation strategy was carried out in order to avoid selective isolation of clonal strains from the same farm. Different capsular serotypes display various clinical

manifestations and differ vastly among countries. The most prevalent capsular gene in the isolates in this study was *cps2*; *cps2+* strains are known to be highly virulent. In this study, *cps2-* strains caused endocarditis and septicemia. This is not surprising, because other *cps2-* serotypes in Europe, particularly with the profile *cps2-/epf-/sly+/mrp+/arcA+*, have proved to be highly virulent and can cause septicemia and meningitis in pigs.<sup>20</sup> We found that *mrp+/sly+/epf+* and *mrp+/sly+/epf-* genotypes were predominant among the tested isolates. The *arcA* gene was identified in all strains, confirming previous studies.<sup>21</sup> From European epidemiological studies<sup>10</sup> and experimental infections in pigs,<sup>22</sup> strains of the *sly+/mrp+/epf+* genotype are known to be highly virulent. This type was significantly associated with systemic infection in pigs and was highly pathogenic to mice.<sup>17</sup> This genotype has also been identified in many isolates from human clinical cases.<sup>20</sup> Though *epf* is not an essential virulence factor for *S suis* serotype 2 strains, it is probably associated with other factors that play a more crucial role in determining virulence and host specificity in *S suis* strains.<sup>23</sup>

Moreover, in this study, resistance of *S suis* to antibiotics commonly used in pig farms in the area was examined. A high rate of

resistance was observed for tetracycline (88.9%) and erythromycin (38.9%). In this study, *S suis* had the greatest susceptibility to beta-lactam antibiotics and the greatest resistance to erythromycin and tetracycline. High rates of resistance to macrolides and tetracyclines suggest widespread resistance to these antibiotics in Italy.<sup>21</sup> In Europe, rising rates of resistance have been attributed to the intensive use by swine breeders of the macrolide-class antibiotics, tylosin as a growth promoter and tetracycline as a therapeutic agent.<sup>20</sup> Co-resistance to macrolides and tetracyclines can be explained by the fact that tetracycline and erythromycin resistance determinants are often linked to mobile genetic elements.<sup>24</sup> The trend of *S suis* resistance to macrolides and tetracyclines has been reported worldwide.<sup>25</sup> Studies of genetic resistance traits have demonstrated that *erm(B)* and *mef(A)* are involved in macrolide resistance, whereas *tet(M)* and *tet(O)* are involved in tetracycline resistance.<sup>21</sup> Resistance to erythromycin is a concern for public health, as macrolide drugs are important for therapeutic treatment of severe streptococcal cases in humans.<sup>17</sup> Resistance of the isolates in the present study to penicillin and ceftiofur was lower than resistance to other tested antibiotics, but was, however,



**Table 4:** Antibiotic resistance phenotype of *Streptococcus suis* cps2+ isolates\*

| Antibiotic                    | S strains (%) | R strains (%) |
|-------------------------------|---------------|---------------|
| Amoxicillin                   | 35 (97.2)     | 1 (2.8)       |
| Amoxicillin-clavulanic acid   | 35 (97.2)     | 1 (2.8)       |
| Ampicillin                    | 36 (100.0)    | 0 (0.0)       |
| Ceftiofur                     | 34 (94.4)     | 2 (5.6)       |
| Enrofloxacin                  | 32 (88.9)     | 4 (11.1)      |
| Erythromycin                  | 22 (61.1)     | 14 (38.9)     |
| Penicillin G                  | 35 (97.2)     | 1 (2.8)       |
| Tetracycline                  | 4 (11.1)      | 32 (88.9)     |
| Trimethoprim-sulfamethoxazole | 30 (83.3)     | 6 (16.7)      |

\* Study described in Table 1. *Streptococcus suis* isolates (n = 36) were tested for susceptibility to antimicrobial agents. No isolates demonstrated intermediate resistance. S = susceptible; R = resistant.

clinically significant. Thus, development of resistance to these antibiotics would reduce the efficacy of antibiotic treatment. To the best of our knowledge, this study represents the first epidemiological investigation of lethal cases of *S suis* infection in piglets in southern Italy (Sardinia). Moreover, this study represents a first attempt to correlate antimicrobial resistance and virulence factors in *S suis* isolated in southern Italy (Sardinia). The results reveal that the majority of *S suis* isolates from dead pigs carry multiple virulence factors and that cps2+ strains display resistance to multiple antimicrobials. Infection with invasive *S suis* requires antibiotic treatment. Possession of both antimicrobial resistance and virulence makes these pathogenic strains potentially highly dangerous to both animal production and public health. Worldwide, *S suis* serotype 2 is the most frequently isolated serotype.

## Implications

- *Streptococcus suis* strains from piglets from participating farms located in southern Italy (Sardinia) were resistant to tetracycline and erythromycin between 2012 and 2014.
- Under the conditions of this study, antimicrobial resistance and genomic virulence factors in *S suis* isolated from swine are not correlated.

## Acknowledgements

We thank Dr Timo G. Lutz for his revision of the language of this manuscript.

## Conflict of interest

None reported.

## Disclaimer

Scientific manuscripts published in the *Journal of Swine Health and Production* are peer reviewed. However, information on medications, feed and management techniques may be specific to the research or commercial situation presented in the manuscript. It is the responsibility of the reader to use this information responsibly and in accordance with the rules and regulations governing research or the practice of veterinary medicine in its country or region.

## References

1. Papatsiros VG, Yourvidis D, Tzitzis A, Meichanetsidis PS, Stougiou D, Mintza D, Papaioannou PS. *Streptococcus suis*: an important zoonotic pathogen for human—prevention aspects. *Vet World*. 2011;4:216–221.
2. Fittipaldi N, Segura M, Grenier D, Gottschalk M. Virulence factors involved in the pathogenesis of the infection caused by the swine pathogen and zoonotic agent *Streptococcus suis*. *Fut Microbiol*. 2012; 7:259–279.
3. Sanford SE, Tilker ME. *Streptococcus suis* type II-associated diseases in swine: observations of a one-year study. *JAVMA*. 1982;181:673–676.
4. Gottschalk M, Segura M, Xu J. *Streptococcus suis* infections in humans: the Chinese experience and the situation in North America. *Anim Health Res Rev*. 2007;8:29–45.
5. Gottschalk M, Xu J, Calzas C, Segura M. *Streptococcus suis*: a new emerging or an old neglected zoonotic pathogen? *Fut Microbiol*. 2010;5:371–391.
6. Camporese A, Tizianel G, Bruschetta G, Cruciatì B, Pomes A. Human meningitis caused by *Streptococcus suis*: the first case report from north-eastern Italy. *Le infezioni in medicina*. 2007;15:111–114.

7. Manzin A, Palmieri C, Serra C, Saddi B, Princivalli MS, Loi G, Angioni G, Tiddia F, Valardo PE, Facinelli B. *Streptococcus suis* meningitis without history of animal contact, Italy. *Emerg Infect Dis*. 2008;14:1946–1948.

8. Goyette-Desjardins G, Auger JP, Xu J, Segura M, Gottschalk M. *Streptococcus suis*, an important pig pathogen and emerging zoonotic agent—an update on the worldwide distribution based on serotyping and sequence typing. *Emerg Microbes Infect*. 2014;3(6):e45.

9. Fittipaldi N, Xu J, Lacouture S, Tharavichitkul P, Osaki M, Sekizaki T, Takamatsu D, Gottschalk M. Lineage virulence of *Streptococcus suis* serotype 2 isolates from North America. *Emerg Infect Disease*. 2011;17:2239–2244.

10. Wisselink HJ, Smith HE, Stockhofe-Zurwieden N, Peperkamp K, Vecht U. Distribution of capsular types and production of muramidase-released protein (MRP) and extracellular factor (EF) of *Streptococcus suis* strains isolated from diseased pigs in seven European countries. *Vet Microbiol*. 2000;74:237–248.

11. Gruening P, Fulde M, Valentin-Weigand P, Goethe R. Structure, regulation, and putative function of the arginine deiminase system of *Streptococcus suis*. *J Bacteriol*. 2006;188:361–369.

12. Smith HE, Damman M, van der Velde J, Wagenaar F, Wisselink HJ, Stockhofe-Zurwieden N, Smits MA. Identification and characterization of the cps locus of *Streptococcus suis* serotype 2: the capsule protects against phagocytosis and is an important virulence factor. *Infect Immun*. 1999;67:1750–1756.

13. Pallares FJ, Schmitt CS, Roth JA, Evans RB, Kinyon JM, Halbur PG. Evaluation of a ceftiofur-washed whole cell *Streptococcus suis* bacterin in pigs. *Can J Vet Res*. 2004;68:236–240.

14. Aarestrup FM, Jorsal SE, Jensen NE. Serological characterization and antimicrobial susceptibility of *Streptococcus suis* isolates from diagnostic samples in Denmark during 1995 and 1996. *Vet Microbiol*. 1998;60:59–66.

15. Marie J, Morvan H, Berthelot HF, Sanders P, Kempf I, Gautier-Bouchardon AV, Jouy E, Kobisch M. Antimicrobial susceptibility of *Streptococcus suis* isolated from swine in France and from humans in different countries between 1996 and 2000. *J Antimicrob Chemother*. 2002;50:201–209.

16. Wei Z, Li R, Zhang A, He H, Hua Y, Xia J, Cai X, Chen H, Jin M. Characterization of *Streptococcus suis* isolates from the diseased pigs in China between 2003 and 2007. *Vet Microbiol*. 2009;137:196–201.

17. Li LL, Liao XP, Sun J, Yang YR, Liu BT, Yang SS, Zhao DH, Liu YH. Antimicrobial resistance, serotypes, and virulence factors of *Streptococcus suis* isolates from diseased pigs. *Foodborne Path Dis*. 2012;9:583–588.

18. Silva LM, Baums CG, Rehm T, Wisselink HJ, Goethe R, Valentin-Weigand P. Virulence-associated gene profiling of *Streptococcus suis* isolates by PCR. *Vet Microbiol*. 2006;115:117–127.

19. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. Approved Standard VET01-A4. 4th ed. Wayne, Pennsylvania: CLSI; 2013.

20. Wisselink HJ, Veldman KT, Van den Eede C, Salmon SA, Mevius DJ. Quantitative susceptibility of *Streptococcus suis* strains isolated from diseased pigs in seven European countries to antimicrobial agents licensed in veterinary medicine. *Vet Microbiol*. 2006;113:73–82.

**Table 5:** Correlation between antimicrobial resistance and virulence factors in *Streptococcus suis* strains\*

| Antibiotic                    | Genotype                | No. of susceptible strains (%) | No. of resistant strains (%) | Total (n) | P†   |
|-------------------------------|-------------------------|--------------------------------|------------------------------|-----------|------|
| Amoxicillin                   | <i>epf</i> <sup>-</sup> | 29 (100.0)                     | 0 (0.0)                      | 29        | .19  |
|                               | <i>epf</i> <sup>+</sup> | 6 (85.7)                       | 1 (14.3)                     | 7         |      |
|                               | Total                   | 35 (97.2)                      | 1 (2.8)                      | 36        |      |
| Amoxicillin-clavulanic acid   | <i>epf</i> <sup>-</sup> | 29 (100.0)                     | 0 (0.0)                      | 29        | .19  |
|                               | <i>epf</i> <sup>+</sup> | 6 (85.7)                       | 1 (14.3)                     | 7         |      |
|                               | Total                   | 35 (97.2)                      | 1 (2.8)                      | 36        |      |
| Penicillin G                  | <i>epf</i> <sup>-</sup> | 29 (100.0)                     | 0 (0.0)                      | 29        | .19  |
|                               | <i>epf</i> <sup>+</sup> | 6 (85.7)                       | 1 (14.3)                     | 7         |      |
|                               | Total                   | 35 (97.2)                      | 1 (2.8)                      | 36        |      |
| Ampicillin                    | <i>epf</i> <sup>-</sup> | 29 (100.0)                     | 0 (0.0)                      | 29        | NA   |
|                               | <i>epf</i> <sup>+</sup> | 7 (100.0)                      | 0 (0.0)                      | 7         |      |
|                               | Total                   | 36 (100.0)                     | 0 (0.0)                      | 36        |      |
| Ceftiofur                     | <i>epf</i> <sup>-</sup> | 27 (93.1)                      | 2 (6.9)                      | 29        | 1.00 |
|                               | <i>epf</i> <sup>+</sup> | 7 (100.0)                      | 0 (0.0)                      | 7         |      |
|                               | Total                   | 34 (94.4)                      | 2 (5.6)                      | 36        |      |
| Enrofloxacin                  | <i>epf</i> <sup>-</sup> | 26 (89.7)                      | 3 (10.3)                     | 29        | 1.00 |
|                               | <i>epf</i> <sup>+</sup> | 6 (85.7)                       | 1 (14.3)                     | 7         |      |
|                               | Total                   | 32 (88.9)                      | 4 (11.1)                     | 36        |      |
| Tetracycline                  | <i>epf</i> <sup>-</sup> | 3 (10.3)                       | 26 (89.7)                    | 29        | 1.00 |
|                               | <i>epf</i> <sup>+</sup> | 1 (14.3)                       | 6 (85.7)                     | 7         |      |
|                               | Total                   | 4 (11.1)                       | 32 (88.9)                    | 36        |      |
| Trimethoprim-sulfamethoxazole | <i>epf</i> <sup>-</sup> | 23 (79.3)                      | 6 (20.7)                     | 29        | .24  |
|                               | <i>epf</i> <sup>+</sup> | 7 (100.0)                      | 0 (0.0)                      | 7         |      |
|                               | Total                   | 30 (83.3)                      | 6 (16.7)                     | 36        |      |
| Erythromycin                  | <i>epf</i> <sup>-</sup> | 19 (65.5)                      | 10 (34.5)                    | 29        | .25  |
|                               | <i>epf</i> <sup>+</sup> | 3 (42.9)                       | 4 (57.1)                     | 7         |      |
|                               | Total                   | 22 (61.1)                      | 14 (38.9)                    | 36        |      |

\* Study described in Table 1.

† Fisher's exact test.  $P < .05$  considered statistically significant.

NA = not applicable. No statistical analyses were performed because ampicillin is a constant.

21. Princivalli MS, Palmieri C, Magi G, Vignaroli C, Manzin A, Camporese A, Barocci S, Magistrali C, Facinelli B. Genetic diversity of *Streptococcus suis* clinical isolates from pigs and humans in Italy (2003-2007). *Eurosurveillance*. 2009;14:1-7.

22. Vecht U, Wisselink H, van Dijk JE, Smith HE. Virulence of *Streptococcus suis* type 2 strains in newborn germfree pigs depends on phenotype. *Infect Immun*. 1992;60:550-556.

23. Baums CG, Verkühlen GJ, Rehm T, Silva LM, Beyerbach M, Pohlmeier K, Valentin-Weigand P. Prevalence of *Streptococcus suis* genotypes in wild boars of Northwestern Germany. *Appl Environ Microbiol*. 2007;73:711-717.

24. Roberts MC. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. *FEMS Microbiol Lett*. 2008; 282:147-159.

25. Palmieri C, Varaldo PE, Facinelli B. *Streptococcus suis*, an emerging drug-resistant animal and human pathogen. *Front Microbiol*. 2011;2:235. <http://dx.doi.org/10.1111/j.1574-6968.2008.01145.x>.



# Efficacy of dietary supplementation of bacteriophages in treatment of concurrent infections with enterotoxigenic *Escherichia coli* K88 and K99 in postweaning pigs

Seung-Jae Han, DVM, MSc; Yeonsu Oh, DVM, PhD; Chul Young Lee, PhD; Jeong-Hee Han, DVM, PhD

## Summary

Postweaning pigs challenged with enterotoxigenic *Escherichia coli* (ETEC) K88 and K99 and fed a diet supplemented with ETEC K88- and K99-specific bacteriophages exhibited greater weight gain, lower fecal consistency score, and less fecal shedding and intestinal adhesion of ETEC K88 than did pigs fed the unsupplemented diet.

**Keywords:** swine, bacteriophage, postweaning diet, enterotoxigenic *Escherichia coli*, feces

**Received:** September 15, 2015

**Accepted:** February 2, 2016

**Resumen - Eficacia de la suplementación dietética de bacteriófagos en el tratamiento de infecciones recurrentes con la *Escherichia coli* enterotoxigénica K88 y K99 en cerdos post-destete**

Los cerdos post-destete probados con *Escherichia coli* enterotoxigénica (ETEC) K88 and K99 y alimentados con una dieta suplementada con bacteriófagos específicos de ETEC K88 y K99 mostraron mayor ganancia de peso, puntaje menor de consistencia fecal, y menos eliminación fecal y adhesión intestinal del ETEC K88 que los cerdos alimentados con una dieta no suplementada.

**Résumé - Efficacité d'un ajout de bactériophages à l'alimentation pour le traitement d'infections concomitantes par *Escherichia coli* K 88 et K99 chez des porcs en période post-sevrage**

Des porcs en période post-sevrage ont été infectés avec des souches entérotoxigènes d'*Escherichia coli* (ETEC) K88 et K99 et nourris avec une diète supplémentée avec des bactériophages spécifiques contre des ETEC K88 et K99. Ceux-ci ont montré un gain de poids supérieur, un score plus faible de la consistance fécale, et moins d'excrétion fécale et d'adhésion intestinale des ETEC K88 que les porcs nourris avec une nourriture non supplémentée.

Postweaning diarrhea or colibacillosis is a costly disease causing substantial mortality, as well as growth retardation, in swine production.<sup>1-3</sup> Colibacillosis is typically associated with avid intestinal adhesion and fecal shedding of enterotoxigenic *Escherichia coli* (ETEC). The ETEC causing diarrhea in postweaning pigs carries the F4 (K88) or F18 fimbrial antigen in most cases.<sup>4-6</sup> The F5 (K99) antigen has also been found in postweaning diarrhea in Central China<sup>7</sup> as well as in South Korea (Jeong-Hee Han, unpublished data, 2014), although piglets are less susceptible to ETEC K99 than to K88 with increasing age.<sup>8</sup>

Common therapies used for prevention and treatment of colibacillosis are antibiotics<sup>9,10</sup>

and pharmacological concentrations of zinc oxide (ZnO) ranging from 2000 to 4000 mg per kg diet in many countries,<sup>2,4,9-11</sup> including the United States.<sup>11</sup> Use of antibiotics as feed additives has been banned in the European Union since 2006, and subsequently in Korea since mid-2011,<sup>12</sup> because of increasing concerns about the emergence of antibiotic-resistant pathogens.<sup>13</sup> Moreover, the concentration of ZnO in feed is now limited to 150 mg per kg by regulation in the European Union,<sup>14</sup> which may lead non-European countries to adopt a similar regulation. It is thus necessary to find alternatives to in-feed antibiotics as well "pharmacological" ZnO.

Bacteriophages or phages have recently received re-emerging attention as alternatives to antibiotics because of several merits as feed additives, including their high stability within the feed and digestive tract as well as their high specificity of transfection.<sup>15-17</sup> However, only limited information is available as to the effects of phage therapy in the pig, although dietary phages have been shown to be effective for alleviating the severity of diarrhea in postweaning pigs challenged with a hemolytic K88-positive ETEC strain as well as in unchallenged piglets.<sup>18</sup> Thus, more studies are needed before dietary phages can be established as prophylactic or therapeutic agents against porcine colibacillosis. The present study was therefore initiated to evaluate the efficacy of dietary phages on treatment of colibacillosis induced by a concurrent oral challenge with ETEC K88 and K99 in postweaning pigs.

## Materials and methods

The experimental protocol for the present study was approved by the Institutional Animal Care and Use Committee of Kangwon National University.

SJH, YO, JHH: Department of Veterinary Pathology, College of Veterinary Medicine, Kangwon National University, Republic of Korea.

CYL: Gyeongnam National University of Science and Technology, Jinju, Republic of Korea.

**Corresponding author:** Dr Jeong-Hee Han, College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon, 24341 Republic of Korea; Tel: +82 33-250-8657; Fax: +82 33-259-5625; E-mail: hanjh@kangwon.ac.kr.

This article is available online at <http://www.aasv.org/shap.html>.

Han SJ, Oh Y, Lee CY, et al. Efficacy of dietary supplementation of bacteriophages in treatment of concurrent infections with enterotoxigenic *Escherichia coli* K88 and K99 in postweaning pigs. *J Swine Health Prod.* 2016;24(5):259-263.



The phages used in the present study were prepared by iNtRON Biotechnology, Inc (Sungnam, Korea), as follows. Briefly, the ETEC K88-specific and K99-specific phages were isolated on agar plates of K88 and K99 bacterial cultures, respectively, from the feces of 30- to 70-day-old grower pigs on a commercial swine farm. The isolated phages, which were identified as *Myoviridae* and *Siphoviridae* families, respectively, were plaque-purified, diluted in a 0.2 M Tris buffer (pH 7.5) containing 0.1 M NaCl, 1 mM MgSO<sub>4</sub>, and 0.01% gelatin, and freeze-dried. The ETEC K88-specific and K99-specific phages added to a common pig diet are known to retain their titers for 12 months (Dr Sang-Hyeon Kang, iNtRON Biotechnology, Inc; oral communication, December, 2015).

Thirty candidate piglets, which had been born to Duroc-sired Landrace × Yorkshire dams on a commercial farm, were castrated on day 2 after birth. Pigs were injected intramuscularly with 4 mg ceftiofur sodium per kg body weight once a day for 3 consecutive days during the suckling period, beginning on day -7 of the experiment, to attempt to remove commensal ETEC if present. Of the 30 candidates, 18 piglets that did not excrete either ETEC K88 or K99, as determined by real-time polymerase chain reaction (PCR) on genomic DNA extracted from feces,<sup>9</sup> were selected at weaning (28 days of age). The animals were transported to a university animal experimental station and allotted arbitrarily to three pens (groups) of six animals each on the day of selection and transportation, corresponding to day 0 of the experiment. Two groups of animals were challenged orally with  $3.0 \times 10^8$  colony-forming units (cfus) of each of ETEC K88 and K99 in a total volume of 6 mL of phosphate buffered saline (pH 7.4). Animals in the remaining group were administered the same volume of vehicle. The ETEC K88 used for the challenge was identified as F4 fimbriae-positive, heat-labile, enterotoxin-positive, hemolysin serogroup O8; ETEC K99 was identified as F5 fimbriae-positive, heat-stable, enterotoxin-positive, hemolysin serogroup O8. The unchallenged group and one challenged group were provided with a basal nursery diet (Control and Chal-Basal groups, respectively) that had been used in previous studies.<sup>9,19,20</sup> The remaining challenged group received the same diet supplemented with  $1.0 \times 10^9$  plaque-forming units of each of ETEC K88- and K99-specific phages per kg (Chal-Phage group). The animals were on the feeding trial for 7 days, beginning on day 0.

Fecal consistency was scored daily beginning on day 1 according to a four-ladder whole-number scale<sup>5</sup> as described previously: 0 = normal feces; 1 = soft feces; 2 = mild diarrhea; 3 = severe diarrhea.<sup>19</sup> Rectal temperature was measured on days 0, 3, and 7 using an electronic thermometer (ThermoScan; Braun GmbH, Kronberg, Germany). Fecal samples were collected on days 1, 3, and 7, also as described previously.<sup>9,19</sup> All animals were euthanized at the end of the 7-day feeding trial. After measuring digesta pH of the stomach, jejunum, and ascending colon using litmus paper (Thomas Scientific, Swedesboro, New Jersey), mucosal tissues from the small intestinal segments and the mesenteric lymph node were collected as described.<sup>18,20</sup> The numbers of ETEC K88 and K99 shed in feces and bound to the tissue were determined by real-time PCR targeting the genes coding for fimbriae K88 and K99, respectively, also as described.<sup>9</sup>

All data were analyzed using the general linear model procedure (SAS 9.2; SAS Institute Inc, Cary, North Carolina), except for fecal shedding and intestinal adhesion of ETEC K88 and K99. The model included treatment only when there was a single observation per animal. In an analysis of repeated measurements, in which the model included treatment, day, and their interaction, the effects of treatment and day, including its interaction with treatment, were tested using animal and day × animal nested within treatment as error terms, respectively. For fecal shedding and intestinal adhesion of ETEC K88 and K99, data from unchallenged animals were excluded from statistical analysis after confirmation of the absence of either pathogen in the feces and intestinal tissues. Frequency of the appearance of pathogen-positive feces and pathogen-positive intestinal tissue were analyzed using the chi-squared test. Means were separated by *t* test;  $P < .05$  was considered statistically significant and  $P < .10$  was considered a tendency.

## Results

The rectal temperature of the Control group did not change during the 7-day experimental period (Table 1). Mean rectal temperature was lower in the Chal-Phage group than in the Chal-Basal group, but did not differ between the Chal-Phage and Control groups. Fecal consistency score increased transiently after day 1 in the challenged groups; mean score was greatest in the Chal-Basal group, followed sequentially

by the Chal-Phage and Control groups. Average daily gain, which was less in the challenged groups than in the Control group, was greater in the Chal-Phage group than in the Chal-Basal group. The digesta pH value measured at necropsy was lower in the Control group than in the Chal-Basal group for the stomach, jejunum, and colon and also in the Chal-Phage group versus the Chal-Basal for the colon, with a tendency to be lower in the Chal-Phage group than in the Chal-Basal for the jejunum ( $P = .07$ ). The ETEC K88 (Figure 1, Panel A) and K99 (Figure 1, Panel B) were detected in feces of the challenged groups, but not the Control group. The mean number of cfus of ETEC K88 transformed to base 10 logarithm (log) per gram feces was greater in the Chal-Basal group than in the Chal-Phage group, but the log number of cfus of ETEC K99 did not differ between the two groups.

The log number of cfus of ETEC K88 bound to the tissue was less in the Chal-Phage group than in the Chal-Basal group for the ileum and cecum, but did not differ between the two groups for the duodenum, jejunum, colon, or mesenteric lymph node (Table 2). Adhesion of ETEC K99, however, did not differ between the two groups in any region of the digestive tract.

## Discussion

Clinical measurements in the present study indicated that the postweaning pigs concurrently challenged with ETEC K88 and K99 developed the intended colibacillosis as manifested by the higher body temperature and fecal consistency score, as well as lower weight gain in the Chal-Basal and Chal-Phage groups versus the Control group, and severity of clinical signs was less in the Chal-Phage group than in the Chal-Basal group. These results, as a whole, were similar to the effects of the ETEC K88 challenge and dietary supplementation of antibiotics or 2500 mg ZnO per kg diet, respectively, in weaning pigs in earlier studies.<sup>9,19</sup>

The greater digesta pH value of the stomach in the Chal-Basal group, compared to the Control group, was consistent with the earlier result of ETEC K88 challenge in weaning pigs,<sup>19</sup> but not with that of the study of Wellock et al,<sup>21</sup> where digesta pH did not change in pigs challenged with ETEC O149 239/03. It thus remains to be determined why different ETEC strains exerted varying effects on gastric acidity. It has been reported that proliferation of beneficial microflora

**Table 1:** Effects of dietary supplementation of enterotoxigenic *Escherichia coli* (ETEC) K88- specific and K99-specific bacteriophages on clinical signs, growth performance, and digesta pH in postweaning pigs challenged with ETEC K88 and K99\*

|                                      | Control            |                      | Challenged            |                    | SEM | P     |
|--------------------------------------|--------------------|----------------------|-----------------------|--------------------|-----|-------|
|                                      | Basal<br>(n = 6)   | Basal<br>(n = 6)     | +Phage<br>(n = 6)     |                    |     |       |
| Rectal temperature (°C)              |                    |                      |                       |                    |     |       |
| Day 0                                | 38.72              | 38.68 <sup>x</sup>   | 38.72 <sup>x</sup>    |                    |     |       |
| Day 3                                | 38.72 <sup>a</sup> | 39.87 <sup>b,y</sup> | 39.05 <sup>c,y</sup>  | 0.097 <sup>†</sup> |     | NA    |
| Day 7                                | 38.68              | 38.90 <sup>x</sup>   | 38.83 <sup>xy</sup>   |                    |     |       |
| Overall <sup>‡</sup>                 | 38.71 <sup>a</sup> | 39.15 <sup>b</sup>   | 38.87 <sup>a</sup>    | 0.057              |     | < .01 |
| Fecal consistency score <sup>§</sup> |                    |                      |                       |                    |     |       |
| Day 1                                | 0.17               | 0.33 <sup>x</sup>    | 0.17 <sup>x</sup>     |                    |     |       |
| Day 2                                | 0.17 <sup>a</sup>  | 1.33 <sup>b,y</sup>  | 0.50 <sup>a,xy</sup>  |                    |     |       |
| Day 3                                | 0.17 <sup>a</sup>  | 2.17 <sup>b,z</sup>  | 1.33 <sup>c,z</sup>   |                    |     |       |
| Day 4                                | 0.33 <sup>a</sup>  | 2.00 <sup>b,z</sup>  | 1.00 <sup>c,yz</sup>  | 0.237 <sup>†</sup> |     | NA    |
| Day 5                                | 0.17 <sup>a</sup>  | 1.33 <sup>b,y</sup>  | 0.67 <sup>a,xy</sup>  |                    |     |       |
| Day 6                                | 0.17 <sup>a</sup>  | 1.17 <sup>b,y</sup>  | 0.50 <sup>a,xy</sup>  |                    |     |       |
| Day 7                                | 0.17 <sup>a</sup>  | 1.00 <sup>b,y</sup>  | 0.50 <sup>ab,xy</sup> |                    |     |       |
| Overall <sup>¶</sup>                 | 0.19 <sup>a</sup>  | 1.33 <sup>b</sup>    | 0.67 <sup>c</sup>     | 0.111              |     | < .01 |
| Growth performance                   |                    |                      |                       |                    |     |       |
| Initial weight (kg)                  | 11.4               | 10.1                 | 10.6                  | 0.46               |     | .18   |
| Final weight (kg)                    | 16.4 <sup>a</sup>  | 11.5 <sup>b</sup>    | 13.2 <sup>c</sup>     | 0.52               |     | < .01 |
| ADG (kg)                             | 0.361 <sup>a</sup> | 0.098 <sup>b</sup>   | 0.186 <sup>c</sup>    | 0.021              |     | < .01 |
| Digesta pH                           |                    |                      |                       |                    |     |       |
| Stomach                              | 2.75 <sup>a</sup>  | 3.65 <sup>b</sup>    | 3.28 <sup>ab</sup>    | 0.188              |     | .02   |
| Jejunum                              | 6.67 <sup>a</sup>  | 7.17 <sup>b</sup>    | 6.87 <sup>ab</sup>    | 0.111              |     | .02   |
| Colon                                | 6.70 <sup>a</sup>  | 7.23 <sup>b</sup>    | 6.80 <sup>a</sup>     | 0.100              |     | < .01 |

\* A total of eighteen 28-day-old postweaning pigs received an oral administration of  $3.0 \times 10^8$  colony-forming units (cfu) of ETEC K88 and of ETEC K89 in 3 mL phosphate buffered saline (PBS) each or 6 mL PBS (Control) on day 0 of the experiment. The animals were fed a nursery diet containing no phage (Basal) or  $1.0 \times 10^9$  plaque-forming units (pfu) of ETEC K88-specific bacteriophages and the same number of pfus of ETEC K99-specific bacteriophages per kg diet (+Phage) for 7 days and were subjected to necropsy, including measurement of digesta pH. Data are means of six animals. Overall average daily feed intakes were 0.406, 0.392, and 0.397 kg per animal for the Control-Basal, Challenged-Basal, and Challenged-Phage groups, respectively.

† Applies to all day  $\times$  treatment combinations.

‡ Both for the day and day  $\times$  treatment  $P < .01$  (ANOVA).

§ 0 = normal feces; 1 = soft feces; 2 = mild diarrhea; 3 = severe diarrhea.

¶ For day and day  $\times$  treatment,  $P < .01$  and  $P = .09$ , respectively (ANOVA).

<sup>a,b,c</sup> Means within a row with no common superscript differ ( $P < .05$ ; t test).

<sup>x,y,z</sup> Means within a column with no common superscript differ ( $P < .05$ ; t test).

SEM = standard error of the mean; ADG = average daily gain; NA = not applicable.

was favored at a lower pH,<sup>22</sup> whereas at higher pH, ETEC colonization was enhanced.<sup>23</sup> It is also well known that ETEC enterotoxins cause electrolyte losses and diarrhea.<sup>2,3,24</sup> Thus, the higher pH of the jejunal digesta, as well as the better fecal consistency score in the Chal-Basal group versus the Control group, which was consistent with the results of Kwon et al<sup>19</sup> and Wellock et al,<sup>21</sup> is likely to have been the result of the


ETEC infection in the Chal-Basal group. Conversely, the lower digesta pH in the colon, as well as the tendency to lower pH in the jejunum for the Chal-Phage group versus the Chal-Basal group, is presumed to have resulted from alleviated ETEC infection as a consequence of the phage therapy.

Fecal shedding and intestinal adhesion of ETEC, which were lower for the K99 strain

than for the K88 strain, were lower in the Chal-Phage group versus the Chal-Basal group for ETEC K88, but not for K99. This may reflect the lower infectivity of the K99 antigen compared with that of K88 in postweaning pigs,<sup>25</sup> although a possibility of confounding effects of ETEC K88 and K99 as well as the two phage strains could not be ruled out under the present experimental conditions.



**Figure 1:** Fecal shedding of *Escherichia coli* (ETEC) K88 (Panel A) and K99 (Panel B) of post-weaned pigs after oral administration of the ETEC K88 and K99 pathogens: effects of in-feed phages. Treatments described in Table 1. Colony forming units (cfus) were transformed to base 10 logarithms. Data are means (with standard error of the means) of six animals. The *P* values for treatment, day, and treatment × day were < .01, < .01, and .26, respectively, for ETEC K88, and .53, .76, and .89, respectively, for ETEC K99 (ANOVA). Chal = challenged.



## Implications

- Phage therapy appears to be effective for treatment of ETEC K88 infection, but not that of K99 infection, in post-weaning pigs.
- More studies on the effects of the ETEC K88-specific phage in piglets infected with ETEC K88 alone are needed.

## Acknowledgements

This work was supported by the College of Veterinary Medicine and Institute of Veterinary Science of Kangwon National University. The authors thank Dr Sang-Hyeon Kang (iNtRON Biotechnology, Inc, Seoul) for providing the ETEC K88-specific and K99-specific bacteriophages used in the present study. Dr Seung-Jae Han and Dr Yeonsu Oh contributed equally to this work.

## Conflict of interest

None reported.

## Disclaimer

Scientific manuscripts published in the *Journal of Swine Health and Production* are peer reviewed. However, information on medications, feed, and management techniques may be specific to the research or commercial situation presented in the manuscript. It is the responsibility of the reader to use information responsibly and in accordance with the rules and regulations governing research or the practice of veterinary medicine in their country or region.

## References

1. Weary DM, Jasper JJ, Hotzel MJ. Understanding weaning stress. *Appl Anim Behav Sci.* 2008;110:24–41.
2. Kim JC, Hansen CF, Mullan BP, Pluske JR. Nutrition and pathology of weaner pigs: nutritional strategies to support barrier function in the gastrointestinal tract. *Anim Feed Sci Technol.* 2012;173:3–16.
3. Heo JM, Opapeju FO, Pluske JR, Kim JC, Hampson DJ, Nyachoti CM. Gastrointestinal health and function in weaned pigs: a review of feeding strategies to control post-weaning diarrhoea without using in-feed antimicrobial compounds. *J Anim Physiol Anim Nutr.* 2013;97:207–237.
4. Huang S, McFall M, Cegielski AC, Kirkwood RN. Effect of dietary zinc supplementation on *Escherichia coli* septicemia in weaned pigs. *Swine Health Prod.* 1999;7:109–111.
5. Marquardt RR, Jin LZ, Kim J-W, Fang L, Frohlich AA, Baidoo SK. Passive protective effect of egg-yolk antibodies against enterotoxigenic *Escherichia coli* K88+ infection in neonatal and early-weaned piglets. *FEMS Immunol Med Microbiol.* 1999;23:283–288.
6. Fairbrother JM, Nadeau E, Gyles CL. *Escherichia coli* in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies. *Anim Health Res Rev.* 2005;6:17–39.

**Table 2:** Effects of dietary supplementation of enterotoxigenic *Escherichia coli* (ETEC) K88-specific and K99-specific bacteriophages on intestinal adhesion of ETEC in postweaning pigs challenged with ETEC K88 and K99\*

|   | Basal<br>(n = 6) | +Phage<br>(n = 6) | P   |
|---|------------------|-------------------|-----|
| ETEC K88, log <sub>10</sub> cfus/g tissue (no. of ETEC-positive pigs) |                  |                   |     |
| Duodenum  | 1.57 ± 0.996 (2) | 0.74 ± 0.738 (1)  | .52 |
| Jejunum   | 3.03 ± 1.37 (3)  | 1.42 ± 0.902 (2)  | .35 |
| Ileum   | 7.24 ± 0.460 (6) | 5.57 ± 0.263 (6)  | .01 |
| Cecum   | 6.32 ± 0.504 (6) | 3.92 ± 0.800 (6)  | .03 |
| Colon   | 3.31 ± 1.510 (3) | 1.84 ± 1.175 (2)  | .46 |
| Mesenteric lymph node   | 3.84 ± 1.233 (4) | 2.19 ± 0.979 (3)  | .32 |
| ETEC K99, log <sub>10</sub> cfus/g tissue (no. of ETEC-positive pigs) |                  |                   |     |
| Duodenum  | 0 (0)            | 0 (0)             | NA  |
| Jejunum   | 2.43 ± 1.108 (3) | 1.42 ± 0.905 (2)  | .50 |
| Ileum   | 2.59 ± 1.184 (3) | 1.52 ± 0.965 (2)  | .50 |
| Cecum   | 1.91 ± 1.238 (2) | 0.83 ± 0.83 (1)   | .49 |
| Colon   | 1.79 ± 1.129 (2) | 0.93 ± 0.932 (1)  | .57 |
| Mesenteric lymph node   | 2.80 ± 1.277 (3) | 2.18 ± 0.984 (3)  | .71 |

\* Treatments described in Table 1. The numbers of cfus of ETEC K88 and K99 were determined by real-time polymerase chain reaction targeting the respective fimbrial genes using genomic DNA extracted from the intestinal tissue as template and were transformed to base 10 logarithms. Data are means ± standard errors of the means of six animals, with the log<sub>10</sub> cfu value for the ETEC-negative animal calculated as 0. The numeral in parenthesis represents the number of the corresponding ETEC-positive animals out of six. The effect of the dietary treatment on the frequency of the corresponding ETEC-positive samples was not significant (chi-squared test) in any of the fecal and tissue samples. Data from Control animals without either ETEC K88 or K99 in fecal or intestinal tissue samples were excluded from this table. Cfus = colony-forming units; NA = not applicable.

7. Wang J, Jiang SW, Chen XH, Liu ZL, Peng J. Prevalence of fimbrial antigen (K88 variants, K99 and 987P) of enterotoxigenic *Escherichia coli* from neonatal and post-weaning piglets with diarrhea in central China. *Asian-Aust J Anim Sci.* 2006;19:1342–1346.

8. Runnels PL, Moon HW, Schneider RA. Development of resistance with host age to adhesion of K99<sup>+</sup> *Escherichia coli* to isolated intestinal epithelial cells. *Infect Immun.* 1980;28:298–300.

9. Kim SJ, Kwon CH, Park BC, Lee CY, Han JH. Effects of a lipid-encapsulated zinc oxide dietary supplement, on growth parameters and intestinal morphology in weaning pigs artificially infected with enterotoxigenic *Escherichia coli*. *J Anim Sci Technol.* 2015;57:4. doi:10.1186/s40781-014-0038-9.

10. Hill GM, Mahan DC, Carter SD, Cromwell GL, Ewan RC, Harrold RL, Lewis AJ, Miller PS, Shurson GC, Veum TL. Effect of pharmacological concentrations of zinc oxide with or without the inclusion of an antibacterial agent on nursery pig performance. *J Anim Sci.* 2001;79:934–941.

11. Piva A, Grilli E, Fabbri L, Pizzamiglio V, Gatta PP, Galvano F, Bognanno M, Fiorentini L, Wolinski J, Zabielki R, Patterson JA. Intestinal metabolism of weaned piglets fed a typical United States or European diet with or without supplementation of tributyrin and lactitol. *J Anim Sci.* 2008;86:2952–2961.

12. Classification and Specification of Hazardous Feeds [in Korean]. Notification No. 2010-142. Ministry of Food, Agriculture, Forestry and Fisheries, Republic of Korea; 2010.

13. Aarestrup FM. Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistant bacteria among food animals. *Int J Antimicrob Agents.* 1999;12:279–285.

14. Amending the conditions for authorization of a number of additives in feedstuffs belonging to the group of trace elements. Commission Regulation (EC) No 1334/2003. *Official J Eur Union.* 2003;L187:11–15.

15. Johnson RP, Gyles CL, Huff WE, Ojha S, Huff GR, Rath NC, Donoghue AM. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs. *Anim Health Res Rev.* 2008;9:201–215.

16. Endersen L, O'Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A. Phage therapy in the food industry. *Annu Rev Food Sci Technol.* 2014;5:327–349.

17. Jamalludeen N, Johnson RP, Shewen PE, Gyles CL. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic *Escherichia coli* O149 infection of pigs. *Vet Microbiol.* 2009;136:135–141.

18. Yoo A, Cha SB, Shin MK, Park HT, Seo HS, Kim JW, Yoo HS. Field evaluation of enterotoxigenic *Escherichia coli*-specific bacteriophage (ΦCJ19) as a feed additive. *Korean J Vet Res.* 2013;53:83–88.

19. Kwon CH, Lee CY, Han SY, Kim SJ, Park BC, Jang I, Han JH. Effects of dietary supplementation of lipid-encapsulated zinc oxide on colibacillosis, growth and intestinal morphology in weaned piglets challenged with enterotoxigenic *Escherichia coli*. *Anim Sci J.* 2014;85:805–813.

20. Jang I, Kwon CH, Ha DM, Jung DY, Kang SY, Park MJ, Han JH, Park BC, Lee CY. Effects of a lipid-encapsulated zinc oxide supplement on growth performance and intestinal morphology and digestive enzyme activities in weaning pigs. *J Anim Sci Technol.* 2014;56:29. doi:10.1186/2055-0391-56-29.

21. Wellock IJ, Fortomaris PD, Houdijk JGM, Kyriazakis I. Effects of dietary protein supply, weaning age and experimental enterotoxigenic *Escherichia coli* infection on newly weaned pigs: health. *Animal.* 2008;2:834–842.

22. Fuller R. The importance of lactobacilli in maintaining normal microbial balance in the crop. *Br Poultry Sci.* 1977;18:85–94.

23. Nagy B, Fekete PZ. Enterotoxigenic *E. coli* (ETEC) in farm animals. *Vet Res.* 1999;30:259–284.

24. Dubreuil JD. The whole shebang: the gastrointestinal tract, *Escherichia coli* enterotoxins and secretion. *Curr Issues Mol Biol.* 2012;14:71–82.

25. Cox E, Houvenaghel A. Comparison of the in vitro adhesion of K88, K99, F41 and P987 positive *Escherichia coli* to intestinal villi of 4- to 5-week-old pigs. *Vet Microbiol.* 1993;34:7–19.



# Fact sheet – Impact of increased feed intake during late gestation on reproductive performance of gilts and sows

Márcio A. D. Gonçalves, DVM, PhD; Steve S. Dritz, DVM, PhD; Mike D. Tokach, MS, PhD; J. H. Piva, DVM; Joel M. DeRouchey, MS, PhD; Jason C. Woodworth, MS, PhD; Robert D. Goodband, MS, PhD

This practice tip includes a fact sheet on the impact of increased feed intake during late gestation on the reproductive performance of gilts and sows

**Keywords:** swine, feeding, gestation, gilts, sows

**Received:** July 24, 2015

**Accepted:** April 28, 2016

## Conflict of interest

None reported.

## Disclaimer

Scientific manuscripts published in the *Journal of Swine Health and Production* are peer reviewed. However, information on medications, feed, and management techniques may be specific to the research or commercial situation presented in the manuscript. It is the responsibility of the reader to use information responsibly and in accordance with the rules and regulations governing research or the practice of veterinary medicine in their country or region.

---

MADG, SSD: Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas.

MDT, JMDR, JCW, RDG: Department of Animal Sciences and Industry, College of Agriculture, Kansas State University, Manhattan, Kansas.

JHP: PIC/Genus, Hendersonville, Tennessee.

**Corresponding author:** Dr Márcio A. D. Gonçalves, Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, College of Agriculture, Kansas State University, Manhattan, Kansas.

Dr Gonçalves is currently with PIC/Genus, 100 Bluegrass Commons Blvd, Hendersonville, TN 37075; Tel: 615-265-2729; Fax: 615-265-2848; [Marcio.Goncalves@GenusPLC.com](mailto:Marcio.Goncalves@GenusPLC.com).

This article is available online at <http://www.aasv.org/shap.html>.

Gonçalves MAD, Dritz SS, Tokach MD, et al. Fact sheet – Impact of increased feed intake during late gestation on reproductive performance of gilts and sows. *J Swine Health Prod.* 2016;24(5):264–266.



# FACT Sheet: Impact of increased feed intake during late gestation on reproductive performance of gilts and sows

“Bump feeding” during late gestation is a widely used practice, generally defined as increasing daily feed intake by about 1 kg from day 90 of gestation to farrowing. The goal is to provide the gestating sow the extra energy and amino acids needed in late gestation to satisfy the exponential growth of the conceptus.<sup>1</sup> Unfortunately, almost all the reported studies in this phase of gestation evaluated increasing feed intake and thus increased intake of all nutrients, including energy, amino acids, vitamins, and minerals. Most likely, as indicated by modeling, the requirement for these nutrients are not increased proportionally.<sup>1</sup> From a practical perspective, increasing feed intake rather than specific nutrients is easier to accomplish, since the daily feed allowance can be increased without the need for a different diet or supplement.

## What is the impact of increasing feed intake in late gestation on sow characteristics?

**Body weight gain.** Increasing feed allowance by 1 kg per day during late gestation increased sow body weight gain by  $6.9 \pm 0.8$  kg (Table 1).<sup>2-4</sup>

**Backfat.** Gilts and sows fed 2.3 kg daily during late gestation lost 1.6 mm of backfat, whereas backfat was not altered in those fed 3.9 kg daily,<sup>5</sup> and this difference was maintained until weaning. However, other research<sup>3</sup> found no evidence that increasing feed intake influenced backfat.

**Lactation feed intake.** Two studies<sup>2,5</sup> had no evidence for differences when evaluating control versus increased feed intake during late gestation, whereas a third study<sup>3</sup> observed that gilts with increased feed intake during late gestation consumed 17% less feed during lactation. However, it has been reported<sup>6</sup> that increased feed allowance during the whole gestation period reduces feed intake during lactation.<sup>6</sup>

**Weight loss during lactation.** One study<sup>2</sup> observed more weight loss during lactation when feed intake was increased from 1.8 to 3.1 kg per day in late gestation, whereas another<sup>3</sup> observed an interaction ( $P = .02$ ) between parity and feeding level in which weight loss during lactation in the subsequent cycle was greater in gilts fed increased feed intake, but there was no difference for sows.

**Wean-to-estrus interval.** Two studies observed no evidence of altered wean-to-estrus interval (WEI),<sup>2,4</sup> whereas one study<sup>3</sup> observed a 0.4-day shorter WEI for gilts fed an extra 0.9 kg per day above maintenance, with no evidence for differences in sows.

## What is the impact of increasing feed intake in late gestation on litter characteristics?

**Total born.** Several studies have observed no evidence for differences in total born when the daily feed allowance was increased beyond the nutritional requirement during late gestation, as expected due to total born being defined in the first third of gestation.<sup>3-5,7</sup> One experiment<sup>2</sup> observed a tendency ( $P < .10$ ) for an increase in total born when gilts

### Fast facts

Each 1 kg per day increase in feed intake increases body weight gain of gilts and sows by 7 kg from day 90 of gestation to farrowing.

Effects of “bump feeding” on individual piglet birth weight are modest, averaging an increase of 28 g per piglet.

The impact on piglet birth weight appears to be related to increased energy rather than amino acid intake.

and sows were fed 3.1 kg per day compared to 1.8 kg per day during late gestation.

**Born alive and stillborn rate.** The impact on born alive and stillborn rate is not consistent between studies. An earlier study<sup>2</sup> observed a tendency for more piglets born alive (9.7 versus 10.0;  $P = .06$ ), whereas other studies<sup>3,5</sup> have observed no difference. A recent study conducted in a large-scale commercial research facility<sup>4</sup> observed a smaller number of born-alive pigs due to a higher stillborn rate (6.5% versus 4.4%) in sows on a high energy intake compared to a low energy intake, but no effect in gilts.

**Total litter birth weight:** Increased feed intake during late gestation had a positive impact in one study<sup>7</sup> for gilt litters; however, three other studies<sup>3-5</sup> observed no differences in total litter birth weight.

**Individual piglet birth weight:** An earlier study<sup>2</sup> observed a 40-g higher individual born-alive piglet birth weight for females fed increased amounts of feed during late gestation, independent of parity. Two additional studies<sup>3,7</sup> observed this positive impact of increasing feed intake during late gestation in gilts, but not in sows. However, individual piglet birth weight might have been confounded with litter size in one of the studies,<sup>3</sup> whereas amino acids might have been deficient in the control diet in the other study.<sup>7</sup> However, a third study<sup>5</sup> evaluated increasing feed intake from a higher basal level (7.5 versus 12.7 ME Mcal per day) than did previous studies and found no differences. A recent study<sup>4</sup> observed that increased feed intake during late gestation increased individual born-alive piglet birth weight by 30 g per piglet. That study observed that this improvement was influenced by high energy rather than high amino-acid intake.

**Pre-weaning mortality.** Several researchers were unable to detect evidence of an influence on pre-weaning mortality when feed intake was increased during late gestation.<sup>2,3,5</sup> A recent study<sup>4</sup> observed a 1.2% reduction in pre-weaning mortality in piglets suckling from females fed 20 g lysine per day compared with females fed 10.7 g lysine per day during late gestation.

**Piglet weaning weight.** While one study<sup>2</sup> observed higher piglet wean weight (5.20 versus 5.37 kg) from females fed increased amounts of feed during late gestation, two others<sup>3,5</sup> observed no differences. Other studies measured birth weight, but not weaning weight.

**Table 1:** Descriptive summary of experiments evaluating increased feed intake during late gestation

| Exp*        | Type      | Start day of gestation | Litters/tx (n) | Total born (n) | Control     |               | Increased feed intake |               | Increased by treatment |                         |
|-------------|-----------|------------------------|----------------|----------------|-------------|---------------|-----------------------|---------------|------------------------|-------------------------|
|             |           |                        |                |                | Mcal ME/day | SID Lys g/day | Mcal ME/day           | SID Lys g/day | Female BW gain†        | Piglet birth weight (g) |
| 2           | Both      | 90                     | 540            | 10.6           | 5.8         | 10.6          | 10.2                  | 18.4          | 5.7                    | 40                      |
| 3           | Gilts     | 90                     | 21             | 14.3           | 6.8         | 11.9          | 9.8                   | 17.1          | 5.7                    | 86                      |
| 3           | Sows      | 90                     | 32             | 12.4           | 7.9         | 11.9          | 11.4                  | 19.9          | 5.4                    | -109                    |
| 4           | Gilts     | 90                     | 371            | 14.2           | 5.9         | 10.7          | 8.9                   | 10.7          | 5.6                    | 24                      |
| 4           | Gilts     | 90                     | 371            | 14.2           | 5.9         | 20.0          | 8.9                   | 20.0          | 9.1                    | 28                      |
| 4           | Sows      | 90                     | 181            | 15.1           | 5.9         | 10.7          | 8.9                   | 10.7          | 9.0                    | 47                      |
| 4           | Sows      | 90                     | 181            | 15.3           | 5.9         | 20.0          | 8.9                   | 20.0          | 10.8                   | 19                      |
| 5           | Both      | 100                    | 57             | 11.2           | 7.5         | 10.8          | 12.7                  | 18.3          | 4.8                    | 10                      |
| 7           | Gilts     | 100                    | 24             | 12.5           | 7.0         | 9.8           | 12.9                  | 18.2          | ND                     | 126                     |
| 7           | Sows      | 100                    | 51             | 12.9           | 7.9         | 11.2          | 13.9                  | 19.5          | ND                     | -69                     |
| <b>Ave‡</b> | <b>NA</b> | <b>90.6</b>            | <b>NA</b>      | <b>12.6</b>    | <b>6.0</b>  | <b>13.5</b>   | <b>9.6</b>            | <b>16.6</b>   | <b>6.9 ± 0.8</b>       | <b>28 ± 20.4</b>        |

\* Experiment number, corresponding to a reference number.

† Body weight (BW) gain expressed as kg/kg of extra daily feed. Assuming a corn-soybean-meal-based diet with 3252 kcal/kg of ME, is the amount in kg of BW gain per kg of extra daily feed above the basal level. For example, if the amount of daily feed is increased from 2 to 3 kg in late gestation, the gilt or sow will be 7 kg heavier at farrowing.

‡ Weighted on the basis of the number of sows in each study.

Tx = treatment; ME = metabolizable energy; SID Lys = standardized ileal digestible lysine; Ave = average; NA = not applicable; ND = not done.

**Estimated economic impact.** An economic model was conducted using a dataset with 5186 individual observations of piglets from birth to carcass.<sup>8</sup> The model accounted for different survivability and growth performance from birth to carcass and assumed 0.9 kg extra feed per day for the last 21 days of gestation at a feed cost of \$0.24 per kg. The estimated impact of changing the population's average piglet birth weight by 28 g has a modest net impact on feed cost of approximately \$0.46 per marketed pig.

On the basis of our review, more research is clearly needed to examine feeding management practices for highly prolific sows. In conclusion, each 1-kg increase in daily feed allowance during late gestation is associated with approximately 7 kg of additional body weight gain for gilts and sows. The impact of increased feed intake during late gestation on piglet birth weight is modest and appears to be associated with an increase in energy rather than amino acid intake. A descriptive summary of the literature showed that piglets from females that received increased feed intake during late gestation were on average 28 ± 20.4 g heavier at birth.

## Acknowledgement

Contribution no. 16-007-J from the Kansas Agricultural Experiment Station, Manhattan, KS 66506-0210.

## References

1. National Research Council. Proteins and amino acids. In: *Nutrient Requirements of Swine*. 11<sup>th</sup> rev ed. Washington, DC: National Academy Press; 2012:15-44.

2. Cromwell GL, Hall DD, Clawson AJ, Combs GE, Knabe DA, Maxwell CV, Noland PR, Orr DE, Prince TJ. Effects of additional feed during late gestation on reproductive performance of sows: A cooperative study. *J Anim Sci*. 1989;67:3-14.

\*3. Shelton NW, Neill CR, DeRouche JM, Tokach MD, Goodband RD, Nelssen JL, Dritz SS. Effects of increasing feeding level during late gestation on sow and litter performance. *Proc Kansas State University Swine Day*. Manhattan, Kansas: Agricultural Experiment Station and Cooperative Extension Service. 2009;38-50.

4. Gonçalves MAD, Gourley K, Dritz SS, Tokach MD, Bello NM, DeRouche JM, Woodworth JC, Goodband RD. Effects of amino acids and energy intake during late gestation of high-performing gilts and sows on litter and reproductive performance under commercial conditions. *J Anim Sci*. 2016;94:1993-2003.

5. Miller HM, Foxcroft GR, Aherne FX. Increasing food intake in late gestation improved sow condition throughout lactation but did not affect piglet viability or growth rate. *Anim Sci*. 2000;71:141-148.

6. Weldon WC, Lewis AJ, Louis GF, Kovar JL, Giesemann MA, Miller PS. Postpartum hypophagia in primiparous sows: I. Effects of gestation feeding level on feed intake, feeding behavior, and plasma metabolite concentrations during lactation. *J Anim Sci*. 1994;72:387-394.

\*7. Soto J, Greiner L, Connor J, Allee G. Effects of increasing feeding levels in sows during late gestation on piglet birth weights [abstract]. *J Anim Sci*. 2011;89:86.

\*8. Matthews N, Jones C, Jungst S. Effect of birth weight on subsequent pig performance. In: *PIC Tech Memo*. Hendersonville, Tennessee. 2009;ES41-338.

\* Non-refereed references.



## Bill Even is new National Pork Board CEO

Just prior to World Pork Expo, the National Pork Board named Bill Even, an agriculture-industry leader with substantial senior management experience in crop and livestock production, as its new chief executive officer. Even began his new role June 6, attending the board's meeting and World Pork Expo in Des Moines, Iowa, in his first official week.

"As a fourth-generation farmer, I have deep, personal knowledge of the challenges facing pork producers today," Even said. "I look forward to working on behalf of America's more than 60,000 pork producers to build

consumer trust, drive sustainable production, and grow consumer pork demand."

Before joining the National Pork Board, Even managed DuPont Pioneer's global industry relations strategy. In that role, he built collaborative stakeholder relationships in the areas of seed, biotechnology, biofuels, and farm policy.

For more information, contact Bill Even at [BEven@pork.org](mailto:BEven@pork.org) or 515-223-2600.



Bill Even

## National Pork Board elects new officers

Jan Archer, a pork producer from Goldsboro, North Carolina, was elected as president of the National Pork Board at the organization's June board meeting in Des Moines, Iowa. The National Pork Board comprises 15 farmer-directors representing America's pig farmers.

"I want to thank my fellow board members for the confidence they are placing in me, and I see much opportunity for our industry in the year ahead," Archer said. "I have been involved in pork production for more than 40 years, and I have never seen a greater level of consumer interest in pig farming. I am proud of the work we do every day on our farms and look forward to sharing our stories of responsible animal production with packers, retail and foodservice customers, and consumers."

Archer and her husband, Jack, are owners of Archer Farms LLC. The sow farm markets 28,000 weaned pigs annually and raises corn, soybeans, and hay. She also operates Archer Consulting, an enterprise that provides personnel training to the pork industry, including certification in Pork Quality Assurance Plus (PQA Plus), Youth PQA Plus, and

Transport Quality Assurance for producers and allied industry representatives.

Serving with Archer on the board as vice president is Terry O'Neel, a pork producer from Friend, Nebraska. Steve Rommereim, a pork producer from Alcester, South Dakota, was named treasurer. Derrick Sleezer, a pork producer from Cherokee, Iowa, will serve as immediate past president. The four executive officers will serve 1-year terms in their positions, beginning July 1.

"We face many challenges, from the threat of emerging diseases to the responsible use of antibiotics," Archer said. "But each issue can be managed from our platform supporting scientific research, producer education, and pork promotion."

Both Archer and O'Neel were confirmed to serve a second 3-year term. Also appointed to the National Pork Board were Gene Noem, Ames, Iowa; Alicia Pedemonti, Hopkinton, New Hampshire; and Michael Skahill, Williamsburg, Virginia.

For more information, contact Jamie Byrnes at [JByrnes@pork.org](mailto:JByrnes@pork.org) or 515-223-2637.



Jan Archer



Terry O'Neel

*NPB News continued on page 269*



PREVENTION  
IS THE KEY



TO UNLOCKING  
YOUR PIGS' TRUE  
POTENTIAL.

Disease prevention can make or break a pig's performance, because healthier pigs reach heavier weights. In fact, we have found that pigs receiving vaccines and raised with other disease prevention protocols weigh more than their less healthy counterparts. Which means if you're not preventing, you're not profiting as much as you could.

To learn more about preventing disease and improving performance,  
visit [www.bi-vetmedica.com/swine](http://www.bi-vetmedica.com/swine).

PREVENTION WORKS.

©2016 Boehringer Ingelheim Vetmedica, Inc. BIVI/SWI/161005a



START HEALTHY. END STRONG.

## Youth exhibitor's guide to new antibiotic rules now available



The Pork Checkoff's Science and Technology team has created a new six-panel brochure aimed at giving youth swine exhibitors the information they need to be compliant with the new antibiotic regulations that go into effect on January 1, 2017.

"We have created several producer-specific resources for adult pork producers, but we didn't have anything specifically for the growing world of youth swine exhibitors on antibiotic changes until now," said Mike King, director of science communications

for the National Pork Board. "We're pleased to offer this new tool to state organizations, 4H clubs, FFA teams, national purebred associations, and others to get the news out to young people about how the new rules could affect them and their show pigs in 2017."

To download a copy or order hard copies, visit [pork.org](http://pork.org) and go to the Antibiotics Resource Center or the Pork Store. For more information contact Mike King at [MKing@pork.org](mailto:MKing@pork.org) or 515-223-3532.

## Animal Science Committee's top five research accomplishments

The mission of the Pork Checkoff's Animal Science Committee is to wisely invest Checkoff funds into research that provides solutions to challenges faced by US pork producers. The areas of research in which they invest must benefit all producers, have significant impact, and be applicable at the farm level. Traditionally, the Animal Science Committee has engaged in research focused on improving the efficiency, productivity, and competitiveness of all producers through improvements in genetics, reproductive efficiency, swine nutrition, and pork quality.

- 1. Development of the PRRS Host Genetics Consortium:** This Consortium effort was a collaboration with the Swine Health Committee, which eventually invested over \$18M in federal, university, and industry support. This effort is also recognized as the largest research collaboration with industry in the history of the United States Department of Agriculture- (USDA-) Agricultural Research Service. The consortium was a unique and extraordinary collaboration of industry, academia, and federal agencies.
- 2. Mapping of the Swine Genome:** The Animal Science Committee, along with several state pork organizations, were critical to the success of this project and in securing federal support by raising the initial funds needed to launch this effort. After the NPB commitment was

established, further funding was then picked up, contributed by the USDA and ultimately Genome Canada. The initial pork industry investment of \$900,000 eventually was leveraged into over \$30 million in additional research by other funding agencies and leveraged producer dollars through financial commitments by other organizations. This also led to the release of the pig genomic map in 2011.

- 3. Consumer Taste and Preference Study:** The intent of the original consumer preference study was to examine consumer perceptions of "Pork Quality," including the cooking temperature and preparation of fresh pork. This study, conducted in partnership with the NPB Domestic Marketing Committee, was unique in that it was conducted nationally and featured a broad cross section of pork consumers. Results indicated the value of pork quality and reinforced taste and tenderness as key attributes of fresh pork. Armed with the results of that study, the Pork Quality and Safety Committee worked with the USDA to safely lower the endpoint cooking temperature of pork from 160°F to 145°F with a 3-minute post-cooking rest.
- 4. Development of the Feed Efficiency Research Consortium:** Support for this consortium was initiated in 2007 in response to the rapidly rising cost of feed grains and concentrates when

the Renewable Fuel Standard was put into place. The original consortium comprised 25 members from the allied industry, commodity boards, and state pork organizations, with the purpose of serving as a vehicle for identifying areas of need and consolidating research related to improving efficiency of utilization of nutrients in swine diets.

- 5. Sow longevity research:** Sow longevity research has been a priority for the NPB and the pork industry for many years. Working with the Animal Science Committee and numerous pork producers, the early research focused on defining the problems and developing mitigation tools and strategies. This early work led to the development of the current Sow Lifetime Productivity effort at the NPB, which is a large-scale, coordinated research effort aimed at increasing the number of quality pigs a female produces from the time she becomes breeding eligible until she leaves the herd.

For more information, contact Chris Hostetler at [CHostetler@pork.org](mailto:CHostetler@pork.org) or 515-223-2606.





**swine influenza**  
WITH ADVANCED ADJUVANTING TECHNOLOGY



Commercial vaccines contain a generic selection of disease isolates from around the country. How can you be sure you are vaccinating with isolates antigenically similar to what is in your client's herd?

Custom Made Vaccines from Newport Laboratories give you the confidence that your herd is vaccinated against the specific isolates found in your area and allows you to address strain variation. Combine that with the ability to customize your vaccine to fit your animal health program and you just found the missing piece.

**Find What You've Been Missing @ Newport Laboratories**

800-220-2522 | [www.newportlabs.com](http://www.newportlabs.com)

*Custom Made Vaccines are sold exclusively through your veterinarian.*



Custom Made Vaccines

**PRRS**

**DIARRHEA**

**MYCO**



# AASV NEWS

## Nominate exceptional colleagues for AASV awards

Do you know an AASV member whose dedication to the association and the swine industry is worthy of recognition? The AASV Awards Committee requests nominations for the following five awards to be presented at the upcoming AASV Annual Meeting in Denver.

### **Howard Dunne Memorial Award** –

Given annually to an AASV member who has made a significant contribution and rendered outstanding service to the AASV and the swine industry.

**Meritorious Service Award** – Given annually to an individual who has consistently given time and effort to the

association in the area of service to the AASV members, AASV officers, and the AASV staff.

**Swine Practitioner of the Year** – Given annually to the swine practitioner (AASV member) who has demonstrated an unusual degree of proficiency in the delivery of veterinary service to his or her clients.

**Technical Services/Allied Industry Veterinarian of the Year** – Given annually to the technical services or allied industry veterinarian who has demonstrated an unusual degree of proficiency and effectiveness in the delivery of veterinary service to his or her company and its clients,

as well as given tirelessly in service to the AASV and the swine industry.

### **Young Swine Veterinarian of the Year** –

Given annually to a swine veterinarian who is an AASV member, 5 years or less post graduation, who has demonstrated the ideals of exemplary service and proficiency early in his or her career.

Nominations are due December 15. The nomination letter should specify the award and cite the qualifications of the candidate for the award. Submit to AASV, 830 26<sup>th</sup> Street, Perry, IA 50220-2328, Fax: 515-465-3832, E-mail: [aasv@aasv.org](mailto:aasv@aasv.org).

## Call for papers – AASV 2017 Student Seminar

The American Association of Swine Veterinarians announces an opportunity for veterinary students to make a scientific presentation during the Student Seminar at the AASV Annual Meeting in Denver, Colorado, on Sunday, February 26, 2017. Interested students are invited to submit a one-page abstract of a research paper, clinical case study, or literature review for consideration. The submitting student must be a current (2016-2017) student member of the AASV at the time of submission and must not have graduated from veterinary school prior to February 26, 2017. Submissions are limited to one (1) abstract per student.

Abstracts and supplementary materials must be received by Dr Maria Pieters ([pieters@aasv.org](mailto:pieters@aasv.org)) by 11:59 PM Central Daylight Time on Wednesday, September 21, 2016 (firm deadline). All material must be submitted electronically. Late abstracts will not be considered. Students will receive an e-mail confirming the receipt of their submission. If they do not receive this confirmation e-mail, they must contact Dr Maria Pieters ([pieters@aasv.org](mailto:pieters@aasv.org)) by Friday, September 23, 2016, with supporting evidence that the submission was made in time; otherwise, the submission will not be considered for

judging. The abstracts will be reviewed by an unbiased professional panel consisting of a private practitioner, an academician, and an industry veterinarian. Fifteen abstracts will be selected for oral presentation in the Student Seminar at the AASV Annual Meeting. Students will be notified by October 14, 2016, and those selected to participate will be expected to provide the complete paper or abstract, reformatted for publication, by November 15, 2016.

As sponsor of the Student Seminar, Zoetis provides a total of \$20,000 in support to fund travel stipends and the Top Student Presenter scholarship. The student presenter of each paper selected for oral presentation receives a \$750 stipend to help defray the costs of attending the AASV meeting.

### **Veterinary Student Scholarships**

Each veterinary student whose paper is selected for oral presentation competes for one of several veterinary student scholarships awarded through the AASV Foundation. The oral presentations will be judged to determine the amount of the scholarship awarded. Zoetis funds the \$5000 scholarship for the student whose paper, oral presenta-

tion, and supporting information are judged best overall. Elanco Animal Health provides \$20,000 in additional funding, enabling the AASV Foundation to award \$2500 each for 2<sup>nd</sup> through 5<sup>th</sup> place, \$1500 each for 6<sup>th</sup> through 10<sup>th</sup> place, and \$500 each for 11<sup>th</sup> through 15<sup>th</sup> place.

Abstracts that are not selected for oral presentation in the Student Seminar will be considered for participation in a poster session at the annual meeting. Zoetis and the AASV fund a stipend of \$250 for each student who is selected and participates in the poster presentation. In addition, the presenters of the top 15 poster abstracts compete for awards ranging from \$200 to \$500 in the Veterinary Student Poster Competition sponsored by Newport Laboratories.

Complete information for preparing and submitting abstracts is available on the AASV Web site at [www.aasv.org/annmtg/2017/studentseminar.htm](http://www.aasv.org/annmtg/2017/studentseminar.htm). Please note: the rules for submission should be followed carefully. For more information, contact the AASV office (Tel: 515-465-5255; Fax: 515-465-3832; E-mail: [aasv@aasv.org](mailto:aasv@aasv.org)).

*AASV news continued on page 273*



 **Draxxin<sup>25</sup>**  
(tulathromycin) mg/ml



# DRAXXIN 25 TREAT AND CONTROL SRD IN SMALL PIGS

**DRAXXIN 25** delivers the proven performance of **DRAXXIN** in a lower concentration for small pigs.

The convenient one-dose treatment is easy to administer and gives you the confidence that your small pigs receive the proper dose for **9** full days of protection.

To learn more about how you can protect your small pigs, speak with your Zoetis representative or visit [www.DRAXXIN.com](http://www.DRAXXIN.com).

#### **Important Safety Information**

The preslaughter withdrawal time for DRAXXIN in swine is 5 days. DRAXXIN should not be used in animals known to be hypersensitive to the product.

**See Brief Summary of Prescribing Information on the next page.**



**Draxxin® 25**  
(tulathromycin injection)  
Injectable Solution

**Antibiotic**  
25 mg of tulathromycin/mL  
For use in suckling calves, dairy calves, veal calves, and swine. Not for use in ruminating cattle.

**Brief Summary**  
**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION**  
DRAXXIN 25 Injectable Solution is a ready-to-use sterile parenteral preparation containing tulathromycin, a semi-synthetic macrolide antibiotic of the subclass triamliide. Each mL of DRAXXIN 25 contains 25 mg of tulathromycin as the free base in a 50% propylene glycol vehicle, monothiolglycerol (5 mg/mL), citric acid (4.8 mg/mL) with hydrochloric acid and sodium hydroxide added to adjust pH. DRAXXIN 25 consists of an equilibrated mixture of two isomeric forms of tulathromycin in a 9:1 ratio. The chemical names of the isomers are (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-(propylamino) methyl]-α-L-ribohexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-2,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-5-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclotetradecan-15-one and (2R,3R,6R,8R,9R,10S,11S,12R)-11-[[2,6-dideoxy-3-C-methyl-3-O-methyl-4-C-(propylamino)methyl]-α-L-ribohexopyranosyl]oxy]-2-[[1R,2R)-1,2-dihydroxy-1-methylbutyl]-8-hydroxy-3,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-1-oxa-4-azacyclotridecan-13-one, respectively.

**INDICATIONS**  
**Swine**  
DRAXXIN 25 Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Haemophilus parasuis*, and *Mycoplasma hyopneumoniae*, and for the control of SRD associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mycoplasma hyopneumoniae* in groups of pigs where SRD has been diagnosed.

**Suckling Calves, Dairy Calves, and Veal Calves**  
**BRD** - DRAXXIN 25 Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Haemophilus somni*, and *Mycoplasma bovis*.

**DOSE AND ADMINISTRATION**  
**Swine**  
Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) body weight (BW). Do not inject more than 4 mL per injection site.

Table 1. DRAXXIN 25 Swine Dosing Guide (25 mg/mL)

| Animal Weight (Pounds) | Dose Volume (mL) |
|------------------------|------------------|
| 4                      | 0.2              |
| 10                     | 0.5              |
| 15                     | 0.7              |
| 20                     | 0.9              |
| 22                     | 1.0              |
| 25                     | 1.1              |
| 30                     | 1.4              |
| 50                     | 2.3              |
| 70                     | 3.2              |
| 90                     | 4.0              |

**Calves**  
Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1 mL/22 lb) body weight (BW). Do not inject more than 11.5 mL per injection site.

Table 2. DRAXXIN 25 Calf Dosing Guide (25 mg/mL)

| Animal Weight (Pounds) | Dose Volume (mL) |
|------------------------|------------------|
| 50                     | 2.3              |
| 75                     | 3.4              |
| 100                    | 4.5              |
| 150                    | 7.0              |
| 200                    | 9.0              |
| 250                    | 11.5             |

**CONTRAINDICATIONS**  
The use of DRAXXIN 25 Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

**WARNINGS**  
**FOR USE IN ANIMALS ONLY.**  
**NOT FOR HUMAN USE.**  
**KEEP OUT OF REACH OF CHILDREN.**  
**NOT FOR USE IN CHICKENS OR TURKEYS.**

**RESIDUE WARNINGS**

**Swine**  
Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.

**Calves**  
Calves intended for human consumption must not be slaughtered within 22 days from the last treatment with DRAXXIN 25 Injectable Solution. This drug is not for use in ruminating cattle.

**PRECAUTIONS**

**Swine**  
The effects of Draxxin 25 Injectable Solution on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

**Cattle**  
The effects of Draxxin 25 Injectable Solution on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

**ADVERSE REACTIONS**

**Swine**  
In one field study, one out of 40 pigs treated with DRAXXIN Injectable Solution (100 mg/mL) at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.

**Calves**  
In one BRD field study, two calves treated with DRAXXIN Injectable Solution (100 mg/mL) at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia.

**Post Approval Experience**

The following adverse events are based on post approval adverse drug experience reporting for DRAXXIN Injectable Solution (100 mg/mL). Not all adverse events are reported to the FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of reporting frequency in cattle: Injection site reactions and anaphylaxis/anaphylactoid reactions. For a complete listing of adverse reactions for DRAXXIN Injectable Solution or DRAXXIN 25 Injectable Solution reported to the CVM see: <http://www.fda.gov/AnimalVeterinary>.  
NADA 141-349, Approved by FDA

**zoetis**  
Distributed by:  
Zoetis Inc.  
Kalamazoo, MI 49007

To report a suspected adverse reaction or to request a safety data sheet call 1-888-963-9471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>. For additional DRAXXIN 25 product information call: 1-888-DRAXXIN or go to [www.DRAXXIN.com](http://www.DRAXXIN.com)



Made in Brazil  
060005AAA&P  
Revised: September 2014

# Call for submissions – Industrial Partners

The American Association of Swine Veterinarians invites submissions for the Industrial Partners portion of the 48<sup>th</sup> AASV Annual Meeting, to be held February 25 to 28, 2017, in Denver, Colorado. This is an opportunity for commercial companies to make brief presentations of a technical, educational nature to members of the AASV.

As in the past, the oral sessions will consist of a series of 15-minute presentations scheduled from 1:00 to 5:00 PM on Sunday afternoon, February 26. A poster session will take place on the same day. Poster authors will be required to be stationed with their poster from 12:00 noon until 1:00 PM, and the posters will remain on display throughout the afternoon and the following day for viewing by meeting attendees.

Restricted program space necessitates a limit on the number of presentations per company. Companies that are members of the *Journal of Swine Health and Production* Industry Support Council (listed on the back cover of each issue of the journal) may submit two topics for oral presentation. All other companies may submit one topic for oral presentation. Sponsors of the AASV e-Letter may submit an additional topic for oral presentation. In addition, every company may submit one topic for poster presentation (poster topics must not duplicate oral presentations). All topics must represent information not previously presented at the AASV Annual Meeting or published in the meeting proceedings.

To participate, send 1) company name, 2) presentation title, 3) a brief description of the presentation content, and 4) contact information for the presenter (name, mailing address, telephone number, and e-mail address) to AASV by **September 30, 2016**. Please identify whether the submission is intended for oral or poster presentation. Send submissions to [aasv@aasv.org](mailto:aasv@aasv.org).

Presenters will be notified of their acceptance by October 14, 2016, and must submit a paper for publication in the meeting proceedings by November 15, 2016. Companies failing to submit papers in a timely manner may not be eligible for future participation in these sessions.


There is no charge for participation in the Industrial Partners sessions, but all presenters are required to register for the meeting (nonmember participants may register at the AASV regular member rate). The AASV does not provide a speaking stipend or travel reimbursement to Industrial Partners presenters.





# Reliable Herd Health Solutions

Since 1981



## MVP Labs Now Part of Phibro Animal Health Corporation

### **Tailor-Made<sup>®</sup> Autogenous BACTERIALS**

- *Strep. suis*, *H. parasuis*, and *A. suis*
- *Mycoplasma hyopneumoniae*,  
*M. hyorhinis*, and *M. hyosynoviae*
- *Clostridium perfringens* (Types A & C)  
and *C. difficile*
- *E. coli*, *E. rhusiopathiae*, and  
*A. pleuropneumoniae*

### **VIRAL VACCINES**

- MJPRRS<sup>®</sup>
- SIV, PEDv, and PDCoV

Potency and efficacy of autogenous biologics have not been established

### **Commercial Vaccines**

- Emulsibac<sup>®</sup>-APP
- Bordetella Bronchiseptica Intranasal

### **Diagnostic Services**

- Trusted and Timely
- Vaccine-Focused

HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD. <sup>®</sup>

# “One World, One Health, One Passion for Pigs”

48<sup>th</sup> Annual Meeting of the  
**American Association of Swine Veterinarians**

**February 25-28, 2017**  
**Denver, Colorado**

**Howard Dunne**  
**Memorial Lecture**

Dr Jeff Zimmerman

**Alex Hogg**  
**Memorial Lecture**

Dr Matthew Turner

**Reserve lodging now:**

Hyatt Regency Denver  
650 15<sup>th</sup> Street  
Denver, CO 80202  
303-436-1234

AASV room rate: \$195 + tax  
Single or double room



**For more information: <https://www.aasv.org/annmtg>**



# Assembling All the Right Elements.

|          |          |                      |           |           |           |           |           |           |
|----------|----------|----------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| 1<br>H   |          |                      |           |           |           |           |           |           |
| 3<br>Li  | 4<br>Be  |                      |           |           |           |           |           |           |
| 11<br>Na | 12<br>Mg |                      |           |           |           |           |           |           |
| 19<br>K  | 20<br>Ca | 21<br>Sc             | 22<br>Ti  | 23<br>V   | 24<br>Cr  | 25<br>Mn  | 26<br>Fe  | 27<br>Co  |
| 37<br>Rb | 38<br>Sr | 39<br>Y              | 40<br>Zr  | C         | E         | V         | A         | 45<br>Rh  |
| 55<br>Cs | 56<br>Ba | 57-71<br>Lanthanides | S         | W         | I         | N         | E         | 77<br>Ir  |
| 87<br>Fr | 88<br>Ra | 89-103<br>Actinides  | 104<br>Rf | 105<br>Db | 106<br>Sg | 107<br>Bh | 108<br>Hs | 109<br>Mt |
|          |          |                      |           |           |           |           |           |           |
| 57<br>La | 58<br>Ce | 59<br>Pr             | 60<br>Nd  | 61<br>Pm  | 62<br>Sm  | 63<br>Eu  |           |           |
| 89<br>Ac | 90<br>Th | 91<br>Pa             | 92<br>U   | 93<br>Np  | 94<br>Pu  | 95<br>Am  |           |           |

## Introducing Ceva Swine.

**Veterinary research. Scientific excellence. Robust development pipeline.**

At Ceva Swine, these are the building blocks to solutions that improve swine health and reproduction, prevent emerging diseases and enhance grow/finish performance – and address other unmet needs in the swine industry. Founded by veterinarians, we are focused on providing the right resources and the right products. Discover the properties that make Ceva Swine an industry leader. [www.ceva.us](http://www.ceva.us)





## Meet, discuss, implore. Repeat as needed.

**I**t was a busy first half of the year on the advocacy front for the American Association of Swine Veterinarians. In May, the AASV leadership (Drs George Charbonneau, Alex Ramirez, and Scanlon Daniels) and staff (Drs Tom Burkgren and Harry Snelson) joined the leadership from the American Association of Bovine Practitioners for our annual government relations meeting in Washington, DC. The American Veterinary Medical Association's Government Relations Division hosted the meeting at their headquarters in Dupont Circle. The group met with regulators, researchers, legislators, and agriculture industry representatives (including the Animal Feed Industry Association, the National Cattlemen's Beef Association, the National Milk Producers Federation, and the National Pork Producers Council [NPPC]) to discuss veterinary and livestock issues.

A key topic of conversation was antimicrobial use. Drs Bill Flynn and Mike Murphy from the Food and Drug Administration (FDA) updated the group on preparations for the January 1, 2017, deadline to transition medically important feed-grade antimicrobials to Veterinary Feed Directive (VFD) status and water medications to prescription. The agency has implemented a pilot project designed to help train FDA compliance personnel on the new VFD rules and to identify gaps in stakeholder education regarding the impending changes, with the goal of targeting educational outreach to address those knowledge gaps. This project is currently ongoing and involves the selection of random VFD forms at feed distributors and tracking those

forms back to the veterinarian and forward to the producer. The investigator will evaluate all aspects of the process, including paperwork accuracy, recordkeeping, proper manufacturing, distribution and administration of the VFD feed, and compliance with the regulation. The goal of this pilot project is to enhance education and promote compliance during the transition.

While in Washington, the AASV leadership met with swine researchers from the Agriculture Research Service and the National Institute for Food and Agriculture. The researchers described swine-related research projects involving animal health, genetics, and production. We provided feedback and thoughts on future challenges facing the swine industry from a veterinary perspective. The group expressed support for continued emphasis on swine research and efforts to increase federal funding for animal agriculture research.

The group also met with Dr Liz Wagstrom, chief veterinarian at the NPPC, to discuss legislative topics of interest to swine producers. The NPPC scheduled meetings with representatives from both the House and Senate Agriculture Committees to give our group an opportunity to offer a veterinary perspective on antimicrobial issues, funding to support on-farm antibiotic-use data collection through the United States Department of Agriculture (USDA), and support for enhancing the foot-and-mouth disease (FMD) vaccine bank.

Regarding USDA's plan to address on-farm antibiotic-use data collection, NPPC has requested federal funding to support projects developed in association with the animal agriculture industries, designed to provide meaningful information to guide implementation of the National Strategy for Combating Antibiotic-Resistant Bacteria (CARB). Congress appropriated approximately \$375 million in additional CARB funding in last year's budget to address human health issues, but none for animal health.

The other significant issue we discussed with the congressional agriculture committees involved securing adequate funding to enhance the FMD vaccine bank currently maintained on Plum Island. Under the current strategy, it would take months to provide an adequate supply of vaccine needed to control a

significant outbreak. In addition, the vaccine bank maintains only a limited number of antigen strains. Due to limited global production of FMD vaccines, there is insufficient surge capacity available to produce the amount of vaccine necessary to begin addressing a large-scale outbreak. We discussed the urgent need to address these challenges.

In addition to the leadership meeting in Washington, AASV staff recently joined with pork producers to discuss similar swine health, production, and trade issues with Mr Kevin Shea, USDA Animal Plant Health Inspection Service administrator, and Dr Jack Shere, USDA chief veterinary officer. These discussions addressed a myriad of issues, including comprehensive swine surveillance, agency funding strategies, plans for addressing information technology needs, Secure Pork Supply, status update on development of the National List of Reportable Animal Diseases, trade support issues, emerging disease response planning, and generally, how to improve the industry's interactions with the Department of Agriculture.

Given today's economic times, funding is a challenging issue. According to Administrator Shea, the agency has seen budget reductions amounting to half a billion dollars over the last few years. It's gotten to the point where we are fighting to maintain adequate funding to support core mission programs integral to the continued health and productivity of animal agriculture in the United States, let alone trying to implement new programs or enhance response capabilities. These meetings all provide an opportunity for face-to-face, one-on-one discussions of issues pertinent to swine health and pork production. Results can be slow to come and the process is often frustrating, but it's necessary if we are going to maintain an emphasis at the federal level on issues of concern to veterinarians and pork producers. You can help as well by taking the opportunity to contact your Congressional representatives to discuss the impact these issues have on your ability to ensure the continued production of safe, wholesome, and economic pork products.

Harry Snelson, DVM  
Director of Communications



# The US Veterinary Feed Directive (VFD) has changed

The new VFD regulation became effective October 1, 2015

The use of any feed-grade antimicrobial with a VFD label is now subject to the new regulation. This includes tilmicosin, florfenicol, and avilamycin, which are already VFD drugs labeled for use in swine.

Pharmaceutical manufacturers will transition other medically important, feed-grade antimicrobials to VFD labels by December 2016. Essentially all swine antibiotics will be affected, except bacitracin, carbadox, bambamycin, ionophores, and tiamulin. These antibiotics will remain available for growth promotion or over-the-counter (OTC) distribution, or both.

The AASV has prepared and mailed a brochure to all US members that highlights the responsibilities of the veterinarian issuing a VFD, the information required on a VFD, the need for a veterinary-client-patient relationship, and additional items of interest. The brochure is available online at [www.aasv.org/aasv/publications.htm](http://www.aasv.org/aasv/publications.htm).

The AASV urges swine veterinarians to become familiar with the regulation, which is available – along with additional information and updates – on the FDA's Veterinary Feed Directive Web page: <http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/ucm071807.htm>.

Changes in the  
Veterinary Feed  
Directive (VFD)

What the swine veterinarian  
needs to know



Extra-label use of feed-grade antimicrobials remains ILLEGAL.

Questions about VFDs?

Contact:

[AskCVM@fda.hhs.gov](mailto:AskCVM@fda.hhs.gov)



# UPCOMING MEETINGS

## 2016 Allen D. Lemman Swine Conference

September 17-20, 2016 (Sat-Tue)  
St Paul RiverCentre, St Paul, Minnesota

For more information:  
University of Minnesota  
Veterinary Continuing Education  
1365 Gortner Avenue  
St Paul, MN 55108  
Web: <http://www.cvm.umn.edu/vetmedce/events/ad1/home.html>

## Leman China Swine Conference

October 16-18, 2016 (Sun-Tue)  
Nanjing, China

For more information:  
Frank Liu  
University of Minnesota  
St Paul, Minnesota  
Tel: 612-625-2267  
E-mail: [liuxf013@umn.edu](mailto:liuxf013@umn.edu)  
Web: <http://www.cvm.umn.edu/lemanchina/>

## 2016 ISU James D. McKean Swine Disease Conference

November 3-4, 2016 (Thu-Fri)  
Hosted by Iowa State University  
Ames, Iowa

For more information:  
E-mail: [registrations@iastate.edu](mailto:registrations@iastate.edu)  
Web: <http://www.extension.iastate.edu/registration/events/conferences/swine/>  
Dr Chris Rademacher, Conference Chair  
Iowa State University  
E-mail: [cjrdvm@iastate.edu](mailto:cjrdvm@iastate.edu)

## 2016 North American PRRS Symposium (NA-PRRS) Emerging and Foreign Animal Diseases

December 3-4, 2016 (Sat-Sun)  
Intercontinental Hotel and Downtown Marriott  
Magnificent Mile in Chicago, Illinois

For more information:  
Web: <http://www.vet.k-state.edu/na-prrs/index.html>

## Banff Pork Seminar

January 10-12, 2017 (Tue-Thu)  
Banff, Alberta, Canada

For more information:  
Tel: 780-492-3651  
E-mail: [pork@ualberta.ca](mailto:pork@ualberta.ca)  
Web: <http://www.banffpork.ca>

## American Association of Swine Veterinarians 48<sup>th</sup> Annual Meeting

February 25-28, 2017 (Sat-Tue)  
Hyatt Regency Denver  
Denver, Colorado

For more information:  
American Association of Swine Veterinarians  
830 26<sup>th</sup> Street  
Perry, IA 50220-2328  
Tel: 515-465-5255; Fax: 515-465-3832  
E-mail: [aasv@aasv.org](mailto:aasv@aasv.org)

## World Pork Expo

June 7-9, 2017 (Wed-Fri)  
Iowa State Fairgrounds  
Des Moines, Iowa

Hosted by the National Pork Producers Council

For more information:  
National Pork Producers Council  
10676 Justin Drive  
Urbandale, IA 50322  
Web: <http://www.worldpork.org>

## 25<sup>th</sup> International Pig Veterinary Society Congress

June 11-14, 2018 (Mon-Thu)  
Chongqing, China

For more information:  
Web: <http://www.ipvs2018.net/>



For additional information on upcoming meetings: <https://www.aasv.org/meetings/>





**American Association of Swine Veterinarians**  
830 26<sup>th</sup> Street  
Perry, IA 50220-2328

PRESORT STD  
US POSTAGE  
PAID  
BROOKFIELD, MO  
PERMIT NO. 50

## PhotoCorner



Feeding time at the University of Missouri farm

*Photo courtesy of Tina Smith*

## AASV Industry Support Council

*Journal of Swine Health and Production*  
is made possible by the generous support of  
the following Industry Support Council members:

|                                     |
|-------------------------------------|
| Boehringer Ingelheim Vetmedica, Inc |
| Ceva Animal Health                  |
| Elanco                              |
| Harrisingredients, Inc              |
| Merck Animal Health                 |
| Newport Laboratories                |
| Norbrook, Inc                       |
| Phibro Animal Health Corporation    |
| Tonistry                            |
| Virox Animal Health                 |
| Zoetis                              |

**AASV Resources online at <https://www.aasv.org>**